S3-Leitlinie „Seltene Lebererkrankungen (LeiSe LebEr) – Autoimmune Lebererkrankungen von der Pädiatrie bis zum Erwachsenenalter“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)

Schlüsselwörter

autoimmune Lebererkrankung - PBC - PSC - diagnostik - therapie - pruritus - seltene Erkrankungen

Keywords

Autoimmune liver disease - PBC - PSC - Diagnostics - Therapy - Pruritus - Rare diseases

^* Beide Autoren haben in gleicher Weise zur Erstellung des Manuskripts beigetragen

Publication History

Received: 11 March 2025

Accepted: 13 March 2025

Article published online:
05 June 2025

• Literatur

• 1 Schünemann H, Brożek J, Guyatt G. et al. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013: The GRADE Working Group. 2013
• 2 Galaski J, Weiler-Normann C, Schakat M. et al. Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. J Hepatol 2021; 74: 312-320
• 3 Zhang WC, Zhao FR, Chen J. et al. Meta-analysis: diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a soluble liver antigen/liver pancreas in autoimmune hepatitis. PLoS One 2014; 9: e92267
• 4 Villalta D, Girolami E, Alessio MG. et al. Autoantibody Profiling in a Cohort of Pediatric and Adult Patients With Autoimmune Hepatitis. J Clin Lab Anal 2016; 30: 41-46
• 5 European Association for the Study of the L. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015; 63: 971-1004
• 6 Vergani D, Alvarez F, Bianchi FB. et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41: 677-683
• 7 Feuchtinger M, Christ S, Preuss B. et al. Detection of novel non-M2-related antimitochondrial antibodies in patients with anti-M2 negative primary biliary cirrhosis. Gut 2009; 58: 983-9
• 8 Mieli-Vergani G, Vergani D, Baumann U. et al. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. J Pediatr Gastroenterol Nutr 2018; 66: 345-360
• 9 Sebode M, Weiler-Normann C, Liwinski T. et al. Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance. Front Immunol 2018; 9: 609
• 10 Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 1993; 18: 1-9
• 11 Tan EM, Feltkamp TE, Smolen JS. et al. Range of antinuclear antibodies in „healthy“ individuals. Arthritis Rheum 1997; 40: 1601-1611
• 12 Hilario MO, Len CA, Roja SC. et al. Frequency of antinuclear antibodies in healthy children and adolescents. Clin Pediatr (Phila) 2004; 43: 637-642
• 13 Czaja AJ, Morshed SA, Parveen S. et al. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology 1997; 26: 567-572
• 14 Czaja AJ, Nishioka M, Morshed SA. et al. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994; 107: 200-207
• 15 Parveen S, Morshed SA, Arima K. et al. Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association. Dig Dis Sci 1998; 43: 1322-1331
• 16 Strassburg CP, Alex B, Zindy F. et al. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases. J Hepatol 1996; 25: 859-866
• 17 Muratori P, Muratori L, Agostinelli D. et al. Smooth muscle antibodies and type 1 autoimmune hepatitis. Autoimmunity 2002; 35: 497-500
• 18 Wiedmann KH, Melms A, Berg PA. Anti-actin antibodies of IgM and IgG class in chronic liver diseases detected by fluorometric immunoassay. Liver 1983; 3: 369-376
• 19 Bottazzo GF, Florin-Christensen A, Fairfax A. et al. Classification of smooth muscle autoantibodies detected by immunofluorescence. J Clin Pathol 1976; 29: 403-410
• 20 Toh BH. Smooth muscle autoantibodies and autoantigens. Clin Exp Immunol 1979; 38: 621-628
• 21 Alvarez F, Berg PA, Bianchi FB. et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938
• 22 Gregorio GV, Portmann B, Reid F. et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25: 541-547
• 23 Gueguen M, Yamamoto AM, Bernard O. et al. Anti-liver-kidney microsome antibody type 1 recognizes human cytochrome P450 db1. Biochem Biophys Res Commun 1989; 159: 542-547
• 24 Manns MP, Johnson EF, Griffin KJ. et al. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 1989; 83: 1066-1072
• 25 Zanger UM, Hauri HP, Loeper J. et al. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 1988; 85: 8256-8260
• 26 Manns MP, Griffin KJ, Sullivan KF. et al. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991; 88: 1370-1378
• 27 Yamamoto AM, Cresteil D, Boniface O. et al. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol 1993; 23: 1105-1111
• 28 Kerkar N, Ma Y, Davies ET. et al. Detection of liver kidney microsomal type 1 antibody using molecularly based immunoassays. J Clin Pathol 2002; 55: 906-909
• 29 Bortolotti F, Vajro P, Balli F. et al. Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol 1996; 25: 614-20
• 30 Dalekos GN, Makri E, Loges S. et al. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. Eur J Gastroenterol Hepatol 2002; 14: 35-42
• 31 Nishioka M, Morshed SA, Kono K. et al. Frequency and significance of antibodies to P450IID6 protein in Japanese patients with chronic hepatitis C. J Hepatol 1997; 26: 992-1000
• 32 Duclos-Vallee JC, Hajoui O, Yamamoto AM. et al. Conformational epitopes on CYP2D6 are recognized by liver/kidney microsomal antibodies. Gastroenterology 1995; 108: 470-476
• 33 Klein R, Zanger UM, Berg T. et al. Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes. Clin Exp Immunol 1999; 118: 290-297
• 34 Bourdi M, Larrey D, Nataf J. et al. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest 1990; 85: 1967-1973
• 35 Clemente MG, Obermayer-Straub P, Meloni A. et al. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1997; 82: 1353-1361
• 36 Beaune P, Dansette PM, Mansuy D. et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987; 84: 551-555
• 37 Crivelli O, Lavarini C, Chiaberge E. et al. Microsomal autoantibodies in chronic infection with the HBsAg associated delta (delta) agent. Clin Exp Immunol 1983; 54: 232-238
• 38 Philipp T, Durazzo M, Trautwein C. et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet 1994; 344: 578-81
• 39 Strassburg CP, Obermayer-Straub P, Alex B. et al. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 1996; 111: 1576-1586
• 40 Csepregi A, Nemesanszky E, Luettig B. et al. LKM3 autoantibodies in hepatitis C cirrhosis: a further phenomenon of the HCV-induced autoimmunity. Am J Gastroenterol 2001; 96: 910-911
• 41 Lapierre P, Hajoui O, Homberg JC. et al. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999; 116: 643-649
• 42 Muratori L, Sztul E, Muratori P. et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology 2001; 34: 494-501
• 43 Han S, Tredger M, Gregorio GV. et al. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology 1995; 21: 58-62
• 44 Muratori L, Cataleta M, Muratori P. et al. Detection of anti-liver cytosol antibody type 1 (anti-LC1) by immunodiffusion, counterimmunoelectrophoresis and immunoblotting: comparison of different techniques. J Immunol Methods 1995; 187: 259-264
• 45 Abuaf N, Johanet C, Chretien P. et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 1992; 16: 892-898
• 46 Lenzi M, Manotti P, Muratori L. et al. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut 1995; 36: 749-754
• 47 Berg PA, Stechemesser E, Strienz J. Hypergammaglobulinämische chronisch aktive Hepatitis mit Nachweis von Leber-Pankreas-spezifischen komplementbindenden Antikörpern. Verh Dtsch Ges Inn Med 1981; 921-927
• 48 Manns M, Gerken G, Kyriatsoulis A. et al. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1: 292-294
• 49 Gelpi C, Sontheimer EJ, Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci USA 1992; 89: 9739-9743
• 50 Costa M, Rodriguez-Sanchez JL, Czaja AJ. et al. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. Clin Exp Immunol 2000; 121: 364-374
• 51 Volkmann M, Martin L, Baurle A. et al. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology 2001; 33: 591-596
• 52 Wies I, Brunner S, Henninger J. et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000; 355: 1510-1515
• 53 Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 2000; 33: 208-215
• 54 Czaja AJ, Manns MP. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am J Gastroenterol 1995; 90: 1206-1211
• 55 Kanzler S, Weidemann C, Gerken G. et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999; 31: 635-640
• 56 Baeres M, Herkel J, Czaja AJ. et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002; 51: 259-264
• 57 Klein R, Eisenburg J, Weber P. et al. Significance and specificity of antibodies to neutrophils detected by western blotting for the serological diagnosis of primary sclerosing cholangitis. Hepatology 1991; 14: 1147-1152
• 58 Roozendaal C, de Jong MA, van den Berg AP. et al. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol 2000; 32: 734-741
• 59 Roozendaal C, Kallenberg CG. Anti-neutrophil cytoplasm autoantibodies (ANCA) in autoimmune liver diseases. Hepatogastroenterology 1999; 46: 3034-3040
• 60 Targan SR, Landers C, Vidrich A. et al. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995; 108: 1159-1166
• 61 Terjung B, Herzog V, Worman HJ. et al. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998; 28: 332-340
• 62 Taubert R, Engel B, Diestelhorst J. et al. Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. Hepatology 2022; 75: 13-27
• 63 Vitozzi S, Djilali-Saiah I, Lapierre P. et al. Anti-soluble liver antigen/liver-pancreas (SLA/LP) antibodies in pediatric patients with autoimmune hepatitis. Autoimmunity 2002; 35: 485-492
• 64 Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413-419
• 65 Mack CL, Adams D, Assis DN. et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology 2020; 72: 671-722
• 66 Lohse AW, Sebode M, Bhathal PS. et al. Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology. Liver Int 2022; 42: 1058-1069
• 67 Covelli C, Sacchi D, Sarcognato S. et al. Pathology of autoimmune hepatitis. Pathologica 2021; 113: 185-193
• 68 Hennes EM, Zeniya M, Czaja AJ. et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76
• 69 Khayat A, Vitola B. Prevalence and Clinical Significance of Autoantibodies in Children with Overweight and Obesity with Nonalcoholic Fatty Liver Disease. J Pediatr 2021; 239: 155-160
• 70 Hoffman A, Rahman F, Prengel S. et al. Mini-laparoscopy in the endoscopy unit: Safety and outcomes in over one thousand patients. World J Gastrointest Endosc 2011; 3: 6-10
• 71 Rockey DC, Caldwell SH, Goodman ZD. et al. Liver biopsy. Hepatology 2009; 49: 1017-1044
• 72 Dechene A, Sowa JP, Schlattjan M. et al. Mini-laparoscopy guided liver biopsy increases diagnostic accuracy in acute liver failure. Digestion 2014; 90: 240-247
• 73 Denzer U, Helmreich-Becker I, Galle PR. et al. Liver assessment and biopsy in patients with marked coagulopathy: value of mini-laparoscopy and control of bleeding. Am J Gastroenterol 2003; 98: 893-900
• 74 de Boer YS, van Nieuwkerk CM, Witte BI. et al. Assessment of the histopathological key features in autoimmune hepatitis. Histopathology 2015; 66: 351-62
• 75 Gurung A, Assis DN, McCarty TR. et al. Histologic features of autoimmune hepatitis: a critical appraisal. Hum Pathol 2018; 82: 51-60
• 76 Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824-32
• 77 Balitzer D, Shafizadeh N, Peters MG. et al. Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. Mod Pathol 2017; 30: 773-783
• 78 Ishak KG, Zimmerman HJ. Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am 1995; 24: 759-786
• 79 Tan CK, Ho D, Wang LM. et al. Drug-induced autoimmune hepatitis: A minireview. World J Gastroenterol 2022; 28: 2654-2666
• 80 Suzuki A, Brunt EM, Kleiner DE. et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011; 54: 931-939
• 81 Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998-1005
• 82 Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008; 48: 1540-1548
• 83 Arcos-Machancoses JV, Molera Busoms C, Julio Tatis E. et al. Accuracy of the Simplified Criteria for Autoimmune Hepatitis in Children: Systematic Review and Decision Analysis. J Clin Exp Hepatol 2019; 9: 147-155
• 84 Hu SL, Zhao FR, Hu Q. et al. Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis. PLoS One 2014; 9: e101916
• 85 Zhang Q, Liu Z, Wu S. et al. Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis. Gastroenterology Research and Practice 2019; 2019: 8959103
• 86 Berg PA, Klein R, Lindenborn-Fotinos J. et al. ATPase-associated antigen (M2): marker antigen for serological diagnosis of primary biliary cirrhosis. Lancet 1982; 2: 1423-1426
• 87 Gershwin ME, Mackay IR, Sturgess A. et al. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987; 138: 3525-3531
• 88 Oertelt S, Rieger R, Selmi C. et al. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007; 45: 659-665
• 89 Dellavance A, Cancado EL, Abrantes-Lemos CP. et al. Humoral autoimmune response heterogeneity in the spectrum of primary biliary cirrhosis. Hepatol Int 2013; 7: 775-784
• 90 Metcalf JV, Mitchison HC, Palmer JM. et al. Natural history of early primary biliary cirrhosis. Lancet 1996; 348: 1399-1402
• 91 Lindenborn-Fotinos J, Baum H, Berg PA. Mitochondrial antibodies in primary biliary cirrhosis: species and nonspecies specific determinants of M2 antigen. Hepatology 1985; 5: 763-769
• 92 Fussey SP, Guest JR, James OF. et al. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci USA 1988; 85: 8654-8658
• 93 Cha S, Leung PS, Gershwin ME. et al. Combinatorial autoantibodies to dihydrolipoamide acetyltransferase, the major autoantigen of primary biliary cirrhosis. Proc Natl Acad Sci USA 1993; 90: 2527-2531
• 94 Mutimer DJ, Fussey SP, Yeaman SJ. et al. Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigens in primary biliary cirrhosis. Hepatology 1989; 10: 403-7
• 95 Walker JG, Doniach D, Roitt IM. et al. Serological Tests in Diagnosis of Primary Biliary Cirrhosis. Lancet 1965; 1: 827-831
• 96 Lindor KD, Gershwin ME, Poupon R. et al. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308
• 97 Berg PA, Klein R. Immunology of primary biliary cirrhosis. Baillieres Clin Gastroenterol 1987; 1: 675-706
• 98 Invernizzi P, Crosignani A, Battezzati PM. et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997; 25: 1090-1095
• 99 Courvalin JC, Lassoued K, Worman HJ. et al. Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis. J Exp Med 1990; 172: 961-967
• 100 Nickowitz RE, Worman HJ. Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210. J Exp Med 1993; 178: 2237-2242
• 101 Szostecki C, Guldner HH, Netter HJ. et al. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J Immunol 1990; 145: 4338-4347
• 102 Invernizzi P, Selmi C, Ranftler C. et al. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005; 25: 298-310
• 103 Wesierska-Gadek J, Penner E, Battezzati PM. et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006; 43: 1135-1144
• 104 Nakamura M, Kondo H, Mori T. et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45: 118-127
• 105 Yang F, Yang Y, Wang Q. et al. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. Aliment Pharmacol Ther 2017; 45: 733-743
• 106 Norman GL, Yang CY, Ostendorff HP. et al. Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int 2015; 35: 642-651
• 107 Bauer A, Habior A, Gawel D. Diagnostic and Clinical Value of Specific Autoantibodies against Kelch-like 12 Peptide and Nuclear Envelope Proteins in Patients with Primary Biliary Cholangitis. Biomedicines 2022; 10
• 108 Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967; 60: 1257-1260
• 109 Nakanuma Y, Ohta G. Quantitation of hepatic granulomas and epithelioid cells in primary biliary cirrhosis. Hepatology 1983; 3: 423-427
• 110 Saxena R, Hytiroglou P, Thung SN. et al. Destruction of canals of Hering in primary biliary cirrhosis. Hum Pathol 2002; 33: 983-988
• 111 Nakanuma Y, Harada K. Florid duct lesion in primary biliary cirrhosis shows highly proliferative activities. J Hepatol 1993; 19: 216-221
• 112 Daniels JA, Torbenson M, Anders RA. et al. Immunostaining of plasma cells in primary biliary cirrhosis. Am J Clin Pathol 2009; 131: 243-249
• 113 Hercun J, Noureddin M, Noureddin N. et al. Longitudinal Assessment of Bile Duct Loss in Primary Biliary Cholangitis. Am J Gastroenterol 2022; 117: 2075-2078
• 114 Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379: 103-112
• 115 Warnes T, Roberts S, Smith A. et al. Liver biopsy in primary biliary cholangitis: is sinusoidal fibrosis the missing key?. J Clin Pathol 2019; 72: 669-676
• 116 Khan FM, Komarla AR, Mendoza PG. et al. Keratin 19 demonstration of canal of Hering loss in primary biliary cirrhosis: „minimal change PBC“?. Hepatology 2013; 57: 700-707
• 117 Overi D, Carpino G, Cristoferi L. et al. Role of ductular reaction and ductular-canalicular junctions in identifying severe primary biliary cholangitis. JHEP Rep 2022; 4: 100556
• 118 Boonstra K, Culver EL, de Buy Wenniger LM. et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology 2014; 59: 1954-1963
• 119 Hov JR, Boberg KM, Karlsen TH. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 2008; 14: 3781-3791
• 120 Wunsch E, Norman GL, Milkiewicz M. et al. Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Aliment Pharmacol Ther 2021; 53: 302-313
• 121 Jendrek ST, Gotthardt D, Nitzsche T. et al. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut 2017; 66: 137-144
• 122 Chapman RW, Arborgh BA, Rhodes JM. et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870-877
• 123 el-Shabrawi M, Wilkinson ML, Portmann B. et al. Primary sclerosing cholangitis in childhood. Gastroenterology 1987; 92: 1226-1235
• 124 Hirschfield GM, Karlsen TH, Lindor KD. et al. Primary sclerosing cholangitis. Lancet 2013; 382: 1587-1599
• 125 Ponsioen CY, Chapman RW, Chazouilleres O. et al. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. Hepatology 2016; 63: 1357-1367
• 126 de Vries EM, Verheij J, Hubscher SG. et al. Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis. J Hepatol 2015; 63: 1212-1219
• 127 Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 11-17
• 128 Bjornsson E, Olsson R, Bergquist A. et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008; 134: 975-980
• 129 Bjornsson E, Chari ST, Smyrk TC. et al. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology 2007; 45: 1547-1554
• 130 Stone JH, Khosroshahi A, Deshpande V. et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 2012; 64: 3061-3067
• 131 Nakazawa T, Shimizu S, Naitoh I. IgG4-Related Sclerosing Cholangitis. Semin Liver Dis 2016; 36: 216-228
• 132 Karlsen TH, Folseraas T, Thorburn D. et al. Primary sclerosing cholangitis – a comprehensive review. J Hepatol 2017; 67: 1298-1323
• 133 Hamano H, Kawa S, Horiuchi A. et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344: 732-738
• 134 Alswat K, Al-Harthy N, Mazrani W. et al. The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. Am J Gastroenterol 2012; 107: 56-63
• 135 Ohara H, Okazaki K, Tsubouchi H. et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci 2012; 19: 536-542
• 136 Naitoh I, Nakazawa T. Classification and Diagnostic Criteria for IgG4-Related Sclerosing Cholangitis. Gut Liver 2022; 16: 28-36
• 137 Hart PA, Zen Y, Chari ST. Recent Advances in Autoimmune Pancreatitis. Gastroenterology 2015; 149: 39-51
• 138 Zen Y, Fujii T, Sato Y. et al. Pathological classification of hepatic inflammatory pseudotumor with respect to IgG4-related disease. Mod Pathol 2007; 20: 884-894
• 139 Watt FE, James OF, Jones DE. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM 2004; 97: 397-406
• 140 Marasini B, Gagetta M, Rossi V. et al. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis 2001; 60: 1046-1049
• 141 Paredes Millan M, Chirinos Montes NJ, Martinez Apaza A. et al. [The most common rheumatic diseases in patients with autoimmune liver disease in the Hospital Arzobispo Loayza from 2008-2013, Lima, Peru]. Rev Gastroenterol Peru 2014; 34: 305-310
• 142 Wang L, Zhang FC, Chen H. et al. Connective tissue diseases in primary biliary cirrhosis: a population-based cohort study. World J Gastroenterol 2013; 19: 5131-5137
• 143 Callichurn K, Cvetkovic L, Therrien A. et al. Prevalence of Celiac Disease in Patients with Primary Biliary Cholangitis. J Can Assoc Gastroenterol 2021; 4: 44-47
• 144 Agakidis C, Agakidou E, Sarafidis K. et al. Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome Associated With a Novel Mutation of FOXP3 Gene. Front Pediatr 2019; 7: 20
• 145 Bjorklund G, Pivin M, Hangan T. et al. Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach. Autoimmun Rev 2022; 21: 103135
• 146 Kleine-Eggebrecht N, Staufner C, Kathemann S. et al. Mutation in ITCH Gene Can Cause Syndromic Multisystem Autoimmune Disease With Acute Liver Failure. Pediatrics 2019; 143
• 147 Wolfe R, Heiman P, D’Annibale O. et al. ITCH deficiency clinical phenotype expansion and mitochondrial dysfunction. Mol Genet Metab Rep 2022; 33: 100932
• 148 Tufano M, Della Corte C, Cirillo F. et al. Fulminant autoimmune hepatitis in a girl with 22q13 deletion syndrome: a previously unreported association. Eur J Pediatr 2009; 168: 225-7
• 149 Bartsch O, Schneider E, Damatova N. et al. Fulminant hepatic failure requiring liver transplantation in 22q13.3 deletion syndrome. Am J Med Genet A 2010; 152A: 2099-2102
• 150 Zeng Q, Zhao L, Wang C. et al. Relationship between autoimmune liver disease and autoimmune thyroid disease: a cross-sectional study. Scand J Gastroenterol 2020; 55: 216-221
• 151 Muratori P, Granito A, Quarneti C. et al. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol 2009; 50: 1210-1218
• 152 Teufel A, Weinmann A, Kahaly GJ. et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol 2010; 44: 208-213
• 153 Werner M, Prytz H, Ohlsson B. et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008; 43: 1232-1240
• 154 Floreani A, Franceschet I, Cazzagon N. et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol 2015; 48: 192-197
• 155 Chen S, Li MQ, Duan WJ. et al. Concomitant extrahepatic autoimmune diseases do not compromise the long-term outcomes of primary biliary cholangitis. Hepatobiliary Pancreat Dis Int 2022; 21: 577-582
• 156 Liu Y, Han K, Liu C. et al. Clinical Characteristics and Prognosis of Concomitant Primary Biliary Cholangitis and Autoimmune Diseases: A Retrospective Study. Can J Gastroenterol Hepatol 2021; 2021: 5557814
• 157 Efe C, Torgutalp M, Henriksson I. et al. Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. J Gastroenterol Hepatol 2021; 36: 936-942
• 158 Floreani A, Mangini C, Reig A. et al. Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers. Am J Gastroenterol 2017; 112: 114-119
• 159 Muratori P, Fabbri A, Lalanne C. et al. Autoimmune liver disease and concomitant extrahepatic autoimmune disease. Eur J Gastroenterol Hepatol 2015; 27: 1175-1179
• 160 Karakaya F, Oztekin S, Ozturk Y. et al. Clinical significance of concomitant extrahepatic autoimmune disease in patients with autoimmune liver disease. Hepatol Forum 2021; 2: 3-6
• 161 Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992; 14: 325-331
• 162 Jiang Y, Xu BH, Rodgers B. et al. Characteristics and Inpatient Outcomes of Primary Biliary Cholangitis and Autoimmune Hepatitis Overlap Syndrome. J Clin Transl Hepatol 2021; 9: 392-398
• 163 Matsumoto T, Morizane T, Aoki Y. et al. Autoimmune hepatitis in primary Sjogren’s syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary Sjogren’s syndrome. Pathol Int 2005; 55: 70-76
• 164 Beisel C, Weiler-Normann C, Teufel A. et al. Association of autoimmune hepatitis and systemic lupus erythematodes: a case series and review of the literature. World J Gastroenterol 2014; 20: 12662-12667
• 165 Boberg KM, Chapman RW, Hirschfield GM. et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54: 374-385
• 166 Abdalian R, Dhar P, Jhaveri K. et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008; 47: 949-957
• 167 Lewin M, Vilgrain V, Ozenne V. et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology 2009; 50: 528-537
• 168 Yoshioka Y, Taniai M, Hashimoto E. et al. Clinical profile of primary biliary cirrhosis with features of autoimmune hepatitis: Importance of corticosteroid therapy. Hepatol Res 2014; 44: 947-955
• 169 Compston J, Cooper A, Cooper C. et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2017; 12: 43
• 170 Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I. et al. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med. 2023
• 171 (DVO) LdDdDWOGeV. Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei Männern. AWMF-Register-Nr.: 183/001 2017.
• 172 Pares A, Guanabens N. Primary biliary cholangitis and bone disease. Best Pract Res Clin Gastroenterol 2018; 34-35: 63-70
• 173 Schmidt T, Schmidt C, Schmidt FN. et al. Disease Duration and Stage Influence Bone Microstructure in Patients With Primary Biliary Cholangitis. J Bone Miner Res 2018; 33: 1011-1019
• 174 Angulo P, Grandison GA, Fong DG. et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011; 140: 180-188
• 175 Schmidt T, Schwinge D, Rolvien T. et al. Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis. J Hepatol 2019; 70: 941-953
• 176 Schmidt T, Schmidt C, Strahl A. et al. A System to Determine Risk of Osteoporosis in Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2020; 18: 226-233
• 177 Bozzini AB, Neder L, Silva CA. et al. Decreased health-related quality of life in children and adolescents with autoimmune hepatitis. J Pediatr (Rio J) 2019; 95: 87-93
• 178 Amevor AA, Yodoshi T, Trout AT. et al. Sarcopenia is highly prevalent in children with autoimmune liver diseases and is linked to visceral fat and parent-perceived general health. Liver Int 2022; 42: 394-401
• 179 Campbell MS, Lichtenstein GR, Rhim AD. et al. Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis. Liver Int 2005; 25: 311-316
• 180 Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I. et al. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med 2023; 176: 224-238
• 181 Zein CO, Jorgensen RA, Clarke B. et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005; 42: 762-771
• 182 Guanabens N, Monegal A, Cerda D. et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology 2013; 58: 2070-2078
• 183 Guanabens N, Pares A, Ros I. et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 2268-2274
• 184 Qaseem A, Forciea MA, McLean RM. et al. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med 2017; 166: 818-839
• 185 Pfeil A, Lehmann G, Lange U. [Update DVO guidelines 2017 on „Prophylaxis, diagnostics and treatment of osteoporosis in postmenopausal women and men“: What is new, what remains for rheumatologists?]. Z Rheumatol 2018; 77: 759-763
• 186 Debray D, Pariente D, Urvoas E. et al. Sclerosing cholangitis in children. J Pediatr 1994; 124: 49-56
• 187 Mieli-Vergani G, Vergani D. Sclerosing cholangitis in the paediatric patient. Best Pract Res Clin Gastroenterol 2001; 15: 681-690
• 188 Ricciuto A, Hansen BE, Ngo B. et al. Primary Sclerosing Cholangitis in Children With Inflammatory Bowel Diseases Is Associated With Milder Clinical Activity But More Frequent Subclinical Inflammation and Growth Impairment. Clin Gastroenterol Hepatol 2020; 18: 1509-1517
• 189 Gulati R, Radhakrishnan KR, Hupertz V. et al. Health-related quality of life in children with autoimmune liver disease. J Pediatr Gastroenterol Nutr 2013; 57: 444-450
• 190 Wu S, Yang Z, Zhou J. et al. Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis. Hepatol Int 2019; 13: 91-101
• 191 Corpechot C, Carrat F, Poujol-Robert A. et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012; 56: 198-208
• 192 Cristoferi L, Calvaruso V, Overi D. et al. Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naive Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach. Hepatology 2021; 74: 1496-1508
• 193 Ehlken H, Wroblewski R, Corpechot C. et al. Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis. PLoS One 2016; 11: e0164224
• 194 Mahmud N, Doshi SD, Forde KA. et al. Transient elastography reliably estimates liver fibrosis in autoimmune hepatitis. Clin Exp Hepatol 2019; 5: 244-249
• 195 Osman KT, Maselli DB, Idilman IS. et al. Liver Stiffness Measured by Either Magnetic Resonance or Transient Elastography Is Associated With Liver Fibrosis and Is an Independent Predictor of Outcomes Among Patients With Primary Biliary Cholangitis. J Clin Gastroenterol 2021; 55: 449-457
• 196 Zachou K, Lygoura V, Arvaniti P. et al. FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases. Ann Hepatol 2021; 22: 100285
• 197 European Association for Study of L, Asociacion Latinoamericana para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-264
• 198 European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guideline P, Chair, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol 2021; 75: 659-689
• 199 Wu HM, Sheng L, Wang Q. et al. Performance of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis-primary biliary cholangitis overlap syndrome. World J Gastroenterol 2018; 24: 737-743
• 200 Ehlken H, Lohse AW, Schramm C. Transient elastography in primary sclerosing cholangitis-the value as a prognostic factor and limitations. Gastroenterology 2014; 147: 542-543
• 201 Shen Y, Chen H, Wu SD. et al. Accuracy of transient elastography in assessing fibrosis at diagnosis in individuals with autoimmune liver disease. J Hepatol 2023; 78: e33-e34
• 202 Corpechot C, Carrat F, Gaouar F. et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. J Hepatol 2022; 77: 1545-1553
• 203 Corpechot C, El Naggar A, Poujol-Robert A. et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006; 43: 1118-1124
• 204 Krawczyk M, Ligocka J, Ligocki M. et al. Does transient elastography correlate with liver fibrosis in patients with PSC? Laennec score-based analysis of explanted livers. Scand J Gastroenterol 2017; 52: 1407-1412
• 205 Corpechot C, Gaouar F, El Naggar A. et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 2014; 146: 970-979
• 206 Cazzagon N, Lemoinne S, El Mouhadi S. et al. The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis. Am J Gastroenterol 2019; 114: 1878-1885
• 207 Hartl J, Ehlken H, Sebode M. et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. J Hepatol 2018; 68: 754-763
• 208 Hartl J, Denzer U, Ehlken H. et al. Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. J Hepatol 2016; 65: 769-775
• 209 Banc-Husu AM, Bass LM. Transient Elastography in Pediatric Liver Disease. J Pediatr Gastroenterol Nutr 2021; 73: 141-144
• 210 Cetiner M, Schiepek F, Finkelberg I. et al. Validation of attenuation imaging coefficient, shear wave elastography, and dispersion as emerging tools for non-invasive evaluation of liver tissue in children. Front Pediatr 2023; 11: 1020690
• 211 Gronbaek L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 2014; 60: 612-617
• 212 Lv T, Li M, Zeng N. et al. Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population. J Gastroenterol Hepatol 2019; 34: 1676-1684
• 213 Sebode M, Kloppenburg A, Aigner A. et al. Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment. Z Gastroenterol 2020; 58: 431-438
• 214 Oettinger R, Brunnberg A, Gerner P. et al. Clinical features and biochemical data of Caucasian children at diagnosis of autoimmune hepatitis. J Autoimmun 2005; 24: 79-84
• 215 Granito A, Muratori L, Pappas G. et al. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment Pharmacol Ther 2005; 21: 1273-1277
• 216 Stravitz RT, Lefkowitch JH, Fontana RJ. et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology 2011; 53: 517-526
• 217 van Gerven NM, Verwer BJ, Witte BI. et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol 2014; 49: 1245-1254
• 218 Feld JJ, Dinh H, Arenovich T. et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62
• 219 Ngu JH, Gearry RB, Frampton CM. et al. Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study. Hepatology 2013; 57: 2399-2406
• 220 Engel B, Laschtowitz A, Janik MK. et al. Genetic aspects of adult and pediatric autoimmune hepatitis: A concise review. Eur J Med Genet 2021; 64: 104214
• 221 Gronbaek L, Vilstrup H, Pedersen L. et al. Family occurrence of autoimmune hepatitis: A Danish nationwide registry-based cohort study. J Hepatol 2018; 69: 873-877
• 222 Kirk AP, Jain S, Pocock S. et al. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980; 21: 78-83
• 223 Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-737
• 224 Soloway RD, Summerskill WH, Baggenstoss AH. et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-833
• 225 Summerskill WH, Korman MG, Ammon HV. et al. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975; 16: 876-883
• 226 Pape S, Snijders R, Gevers TJG. et al. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. J Hepatol 2022; 76: 841-849
• 227 Laschtowitz A, Zachou K, Lygoura V. et al. Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis. JHEP Rep 2021; 3: 100321
• 228 Dufour JF, Zimmermann M, Reichen J. Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare. J Hepatol 2002; 37: 748-752
• 229 Pape S, Gevers TJG, Vrolijk JM. et al. Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months. Clin Gastroenterol Hepatol 2020; 18: 1609-1617
• 230 Lohse AW, Sebode M, Jorgensen MH. et al. Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. J Hepatol 2020; 73: 1496-1506
• 231 Kirstein MM, Metzler F, Geiger E. et al. Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology 2015; 62: 1524-1535
• 232 Biewenga M, Verhelst X, Baven-Pronk M. et al. Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis. Clin Gastroenterol Hepatol 2022; 20: 1776-1783
• 233 Al-Chalabi T, Portmann BC, Bernal W. et al. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008; 28: 209-220
• 234 Al-Chalabi T, Underhill JA, Portmann BC. et al. Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin Gastroenterol Hepatol 2008; 6: 1389-1395
• 235 Al-Chalabi T, Underhill JA, Portmann BC. et al. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008; 48: 140-7
• 236 Narkewicz MR, Horslen S, Belle SH. et al. Prevalence and Significance of Autoantibodies in Children With Acute Liver Failure. J Pediatr Gastroenterol Nutr 2017; 64: 210-217
• 237 Junge N, Tiedau M, Verboom M. et al. Human leucocyte antigens and pediatric autoimmune liver disease: diagnosis and prognosis. Eur J Pediatr 2016; 175: 527-37
• 238 van Gerven NM, de Boer YS, Zwiers A. et al. HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. Genes Immun 2015; 16: 247-252
• 239 Lamers MM, van Oijen MG, Pronk M. et al. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol 2010; 53: 191-198
• 240 Lu FB, Hu ED, Xu LM. et al. Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta-analysis. Exp Ther Med 2018; 15: 4838-4850
• 241 Gordon V, Adhikary R, Appleby V. et al. Treatment and Outcome of Autoimmune Hepatitis (AIH): Audit of 28 UK centres. Liver Int 2022;
• 242 Pape S, Gevers TJG, Belias M. et al. Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2019; 17: 2068-2075
• 243 Zhang C, Wu SS, Dong XQ. et al. The efficacy and safety of different doses of glucocorticoid for autoimmune hepatitis: A systematic review and meta-analysis. Medicine (Baltimore) 2019; 98: e18313
• 244 Manns MP, Woynarowski M, Kreisel W. et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-1206
• 245 Woynarowski M, Nemeth A, Baruch Y. et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr 2013; 163: 1347-1353
• 246 Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-185
• 247 Diaz-Gonzalez A, Hernandez-Guerra M, Perez-Medrano I. et al. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration. Hepatology 2023;
• 248 Peiseler M, Liebscher T, Sebode M. et al. Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2018; 16: 260-267
• 249 Geier A, Gartung C, Dietrich CG. et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003; 9: 2681-2685
• 250 Efe C, Ozaslan E, Kav T. et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev 2012; 11: 330-334
• 251 Hempfling W, Grunhage F, Dilger K. et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003; 38: 196-202
• 252 Snijders R, Stoelinga AEC, Gevers TJG. et al. Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial. Trials 2022; 23: 1012
• 253 De Martin E, Coilly A, Chazouilleres O. et al. Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score. J Hepatol 2021; 74: 1325-1334
• 254 Czaja AJ, Beaver SJ, Wood JR. et al. Frequency and significance of serum alpha-fetoprotein elevation in severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1987; 93: 687-692
• 255 Tellez L, Sanchez Rodriguez E, Rodriguez de Santiago E. et al. Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study. Aliment Pharmacol Ther 2022; 56: 131-143
• 256 Durazzo M, Lupi G, Scandella M. et al. Autoimmune hepatitis treatment in the elderly: A systematic review. World J Gastroenterol 2019; 25: 2809-2818
• 257 Vajro P, Fischler B, Burra P. et al. The Health Care Transition of Youth With Liver Disease Into the Adult Health System: Position Paper From ESPGHAN and EASL. J Pediatr Gastroenterol Nutr 2018; 66: 976-990
• 258 Vittorio J, Kosmach-Park B, King LY. et al. Health Care Transition for Adolescents and Young Adults With Pediatric-Onset Liver Disease and Transplantation: A Position Paper by the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2023; 76: 84-101
• 259 Di Giorgio A, Bravi M, Bonanomi E. et al. Fulminant hepatic failure of autoimmune aetiology in children. J Pediatr Gastroenterol Nutr 2015; 60: 159-164
• 260 Yeoman AD, Westbrook RH, Zen Y. et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol 2014; 61: 876-882
• 261 Rahim MN, Miquel R, Heneghan MA. Approach to the patient with acute severe autoimmune hepatitis. JHEP Rep 2020; 2: 100149
• 262 Yeoman AD, Westbrook RH, Zen Y. et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011; 53: 926-934
• 263 Biewenga M, Inderson A, Tushuizen ME. et al. Early Predictors of Short-Term Prognosis in Acute and Acute Severe Autoimmune Hepatitis. Liver Transpl 2020; 26: 1573-1581
• 264 Noguchi F, Chu PS, Yoshida A. et al. Early Dynamics of MELD Scores Predict Corticosteroid Responsiveness to Severe Acute-Onset Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2022; 20: 2641-2643
• 265 Lin S, Hall A, Kumar R. et al. Validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis. J Hepatol 2022; 76: 485-487
• 266 Heldman MR, Sohn MW, Gordon EJ. et al. National survey of adult transplant hepatologists on the pediatric‐to‐adult care transition after liver transplantation. Liver Transplantation 2015; 21
• 267 Fredericks EM, Dore-Stites D, Well A. et al. Assessment of transition readiness skills and adherence in pediatric liver transplant recipients. Pediatr Transplant 2010; 14: 944-953
• 268 Heneghan MA, Allan ML, Bornstein JD. et al. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006; 45: 584-591
• 269 Dhaliwal HK, Anderson R, Thornhill EL. et al. Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology 2012; 56: 1401-1408
• 270 Schramm C, Wahl I, Weiler-Normann C. et al. Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. J Hepatol 2014; 60: 618-624
• 271 Sockalingam S, Blank D, Abdelhamid N. et al. Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors. J Hepatol 2012; 57: 1299-1304
• 272 Wong LL, Fisher HF, Stocken DD. et al. The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility. Hepatology 2018; 68: 1487-1497
• 273 Michel M, Spinelli F, Grambihler A. et al. Health-related quality of life in patients with autoimmune hepatitis. Qual Life Res 2021; 30: 2853-2861
• 274 Janik MK, Wunsch E, Raszeja-Wyszomirska J. et al. Autoimmune hepatitis exerts a profound, negative effect on health-related quality of life: A prospective, single-centre study. Liver Int 2019; 39: 215-221
• 275 Takahashi A, Moriya K, Ohira H. et al. Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey. PLoS One 2018; 13: e0204772
• 276 Jalal MI, Brahmbhatt M, Green K. et al. Autoimmune hepatitis and metabolic syndrome-associated disease development: a U.S. cohort study. Aliment Pharmacol Ther 2022; 56: 1183-1193
• 277 Snijders RJ, Milkiewicz P, Schramm C. et al. Health-related quality of life in autoimmune hepatitis. World J Hepatol 2021; 13: 1642-1652
• 278 Wunsch E, Krause L, Gevers TJ. et al. Confidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of ERN RARE-LIVER online survey. Liver Int 2023; 43: 381-392
• 279 Harter M, Prien P, Group NVLG. Clinical Practice Guideline: The Diagnosis and Treatment of Unipolar Depression- National Disease Management Guideline. Dtsch Arztebl Int 2023;
• 280 Dolle K, Schulte-Korne G. The treatment of depressive disorders in children and adolescents. Dtsch Arztebl Int 2013; 110: 854-860
• 281 Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010; 59: 1410-1415
• 282 Chalasani S, Mathur K, Shammas N. et al. Hepatic steatosis is highly prevalent but is not correlated with stiffness in autoimmune hepatitis. Medicine (Baltimore) 2020; 99: e22805
• 283 De Luca-Johnson J, Wangensteen KJ, Hanson J. et al. Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2016; 61: 2710-2720
• 284 Candels LS, Rahim MN, Shah S. et al. Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates. J Hepatol 2021; 75: 324-332
• 285 Bak-Drabik K, Adamczyk P, Duda-Wronska J. et al. Usefulness of Measuring Thiopurine Metabolites in Children with Inflammatory Bowel Disease and Autoimmunological Hepatitis, Treated with Azathioprine. Gastroenterol Res Pract 2021; 2021: 9970019
• 286 Zizzo AN, Valentino PL, Shah PS. et al. Second-line Agents in Pediatric Patients With Autoimmune Hepatitis: A Systematic Review and Meta-analysis. J Pediatr Gastroenterol Nutr 2017; 65: 6-15
• 287 Efe C, Taii HA, Ytting H. et al. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis. Dig Dis Sci 2018; 63: 1348-1354
• 288 Abdollahi M, Ekrami NK, Ghojazadeh M. et al. Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations?. World J Gastroenterol 2020; 26: 5896-5910
• 289 Nastasio S, Sciveres M, Matarazzo L. et al. Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine. Dig Liver Dis 2019; 51: 712-718
• 290 Hoeroldt B, McFarlane E, Dube A. et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011; 140: 1980-9
• 291 Verma S, Gunuwan B, Mendler M. et al. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 1510-1516
• 292 Hindorf U, Jahed K, Bergquist A. et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2010; 52: 106-111
• 293 Bolia R, Goel A, Srivastava A. Systematic Review and Meta-Analysis of Thiopurine Metabolite Levels and Biochemical Remission in Autoimmune Hepatitis. Ther Drug Monit 2021; 43: 609-616
• 294 Sheiko MA, Sundaram SS, Capocelli KE. et al. Outcomes in Pediatric Autoimmune Hepatitis and Significance of Azathioprine Metabolites. J Pediatr Gastroenterol Nutr 2017; 65: 80-85
• 295 Nguyen TM, Daubard M, Le Gall C. et al. Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis. Ther Drug Monit 2010; 32: 433-437
• 296 de Boer YS, van Gerven NM, de Boer NK. et al. Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis. Aliment Pharmacol Ther 2013; 37: 640-646
• 297 Santiago P, Schwartz I, Tamariz L. et al. Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. Aliment Pharmacol Ther 2019; 49: 830-839
• 298 De Lemos-Bonotto M, Valle-Tovo C, Costabeber AM. et al. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment. Eur J Gastroenterol Hepatol 2018; 30: 212-216
• 299 Nicoll AJ, Roberts SK, Lim R. et al. Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. Aliment Pharmacol Ther 2019; 49: 1314-1322
• 300 Hanouneh M, Ritchie MM, Ascha M. et al. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis. Scand J Gastroenterol 2019; 54: 76-80
• 301 Efe C, Ozaslan E, Purnak T. Second-line immunosuppressants for autoimmune hepatitis. Eur J Gastroenterol Hepatol 2018; 30: 490-491
• 302 Marlaka JR, Papadogiannakis N, Fischler B. et al. Tacrolimus without or with the addition of conventional immunosuppressive treatment in juvenile autoimmune hepatitis. Acta Paediatr 2012; 101: 993-999
• 303 van Gerven NM, Verwer BJ, Witte BI. et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 2013; 58: 141-147
• 304 Ben MerabetY, Barbe C, Heurgue-Berlot A. et al. Sustained Remission After Treatment Withdrawal in Autoimmune Hepatitis: A Multicenter Retrospective Study. Dig Dis Sci 2021; 66: 2107-2117
• 305 Cavus B, Akyuz F, Iliaz R. et al. Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life?. Int J Immunopathol Pharmacol 2022; 36: 3946320221077860
• 306 Guirguis J, Alonso Y, Lopez R. et al. Well-controlled autoimmune hepatitis treatment withdrawal may be safely accomplished without liver-biopsy guidance. Gastroenterol Rep (Oxf) 2018; 6: 284-290
• 307 Hartl J, Ehlken H, Weiler-Normann C. et al. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. J Hepatol 2015; 62: 642-646
• 308 Mieli-Vergani G, Vergani D. Autoimmune paediatric liver disease. World J Gastroenterol 2008; 14: 3360-7
• 309 Jimenez-Rivera C, Ling SC, Ahmed N. et al. Incidence and Characteristics of Autoimmune Hepatitis. Pediatrics 2015; 136: e1237-e1248
• 310 Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007; 102: 1005-1012
• 311 Teufel A, Weinmann A, Centner C. et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol 2009; 15: 578-582
• 312 Yeoman AD, Al-Chalabi T, Karani JB. et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology 2008; 48: 863-70
• 313 Ngu JH, Gearry RB, Frampton CM. et al. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 2012; 55: 522-529
• 314 Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 2008; 103: 1944-1951
• 315 Voesch S, Bitzer M, Blodt S. et al. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms und biliärer Karzinome – Version 2. 0 – Juni 2021, AWMF-Registernummer: 032-053OL. Z Gastroenterol 2022; 60: e131-e185
• 316 Beuers U, Gershwin ME, Gish RG. et al. Changing nomenclature for PBC: From “cirrhosis” to “cholangitis”. J Hepatol 2015; 63: 1285-1287
• 317 Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012; 56: 1181-1188
• 318 Lu M, Li J, Haller IV. et al. Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems. Clin Gastroenterol Hepatol 2018; 16: 1333-1341
• 319 European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017; 67: 145-172
• 320 Lindor KD, Bowlus CL, Boyer J. et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2019; 69: 394-419
• 321 Mattalia A, Quaranta S, Leung PS. et al. Characterization of antimitochondrial antibodies in health adults. Hepatology 1998; 27: 656-661
• 322 Dahlqvist G, Gaouar F, Carrat F. et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology 2017; 65: 152-163
• 323 Zandanell S, Strasser M, Feldman A. et al. Low rate of new-onset primary biliary cholangitis in a cohort of anti-mitochondrial antibody-positive subjects over six years of follow-up. J Intern Med 2020; 287: 395-404
• 324 Nakanuma Y, Zen Y, Harada K. et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int 2010; 60: 167-174
• 325 Kakuda Y, Harada K, Sawada-Kitamura S. et al. Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. Hum Pathol 2013; 44: 1107-1117
• 326 Corpechot C, Wendum D. Primary biliary cirrhosis: is there still a place for histological evaluation?. Clin Res Hepatol Gastroenterol 2013; 37: 556-558
• 327 Nakanuma Y. Primary biliary cirrhosis: is there still a place for histological evaluation?. Clin Res Hepatol Gastroenterol 2014; 38: e1-e2
• 328 Barreiros AP, Chiorean L, Braden B. et al. Ultrasound in rare diffuse liver disease. Z Gastroenterol 2014; 52: 1247-1256
• 329 Braden B, Faust D, Ignee A. et al. Clinical relevance of perihepatic lymphadenopathy in acute and chronic liver disease. J Clin Gastroenterol 2008; 42: 931-6
• 330 Soresi M, Bonfissuto G, Magliarisi C. et al. Ultrasound detection of abdominal lymph nodes in chronic liver diseases. A retrospective analysis. Clin Radiol 2003; 58: 372-377
• 331 Lazaridis KN, Juran BD, Boe GM. et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 2007; 46: 785-792
• 332 Mantaka A, Koulentaki M, Chlouverakis G. et al. Primary biliary cirrhosis in a genetically homogeneous population: disease associations and familial occurrence rates. BMC Gastroenterol 2012; 12: 110
• 333 Galbraith RM, Smith M, Mackenzie RM. et al. High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis. N Engl J Med 1974; 290: 63-69
• 334 Caldwell SH, Leung PS, Spivey JR. et al. Antimitochondrial antibodies in kindreds of patients with primary biliary cirrhosis: antimitochondrial antibodies are unique to clinical disease and are absent in asymptomatic family members. Hepatology 1992; 16: 899-905
• 335 Zografos TA, Gatselis N, Zachou K. et al. Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients. World J Gastroenterol 2012; 18: 4721-4728
• 336 Hegade VS, Mells GF, Fisher H. et al. Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom. Clin Gastroenterol Hepatol 2019; 17: 1379-1387
• 337 Long RG, Scheuer PJ, Sherlock S. Presentation and course of asymptomatic primary biliary cirrhosis. Gastroenterology 1977; 72: 1204-7
• 338 Roll J, Boyer JL, Barry D. et al. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983; 308: 1-7
• 339 Nyberg A, Loof L. Primary biliary cirrhosis: clinical features and outcome, with special reference to asymptomatic disease. Scand J Gastroenterol 1989; 24: 57-64
• 340 Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994; 20: 707-13
• 341 Prince M, Chetwynd A, Newman W. et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002; 123: 1044-1051
• 342 Mitchison HC, Lucey MR, Kelly PJ. et al. Symptom development and prognosis in primary biliary cirrhosis: a study in two centers. Gastroenterology 1990; 99: 778-784
• 343 Springer J, Cauch-Dudek K, O’Rourke K. et al. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999; 94: 47-53
• 344 Huet PM, Deslauriers J, Tran A. et al. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol 2000; 95: 760-767
• 345 Poupon RE, Chretien Y, Chazouilleres O. et al. Quality of life in patients with primary biliary cirrhosis. Hepatology 2004; 40: 489-494
• 346 Cauch-Dudek K, Abbey S, Stewart DE. et al. Fatigue in primary biliary cirrhosis. Gut 1998; 43: 705-710
• 347 Goldblatt J, Taylor PJ, Lipman T. et al. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 2002; 122: 1235-1241
• 348 Beuers U, Kremer AE, Bolier R. et al. Pruritus in cholestasis: facts and fiction. Hepatology 2014; 60: 399-407
• 349 Kaps L, Grambihler A, Yemane B. et al. Symptom Burden and Treatment Response in Patients with Primary Biliary Cholangitis (PBC). Dig Dis Sci 2020; 65: 3006-3013
• 350 Talwalkar JA, Souto E, Jorgensen RA. et al. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003; 1: 297-302
• 351 Mang FW, Michieletti P, O’Rourke K. et al. Primary biliary cirrhosis, sicca complex, and dysphagia. Dysphagia 1997; 12: 167-170
• 352 Stefanski AL, Tomiak C, Pleyer U. et al. The Diagnosis and Treatment of Sjogren’s Syndrome. Dtsch Arztebl Int 2017; 114: 354-361
• 353 Allocca M, Crosignani A, Gritti A. et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 2006; 55: 1795-1800
• 354 Longo M, Crosignani A, Battezzati PM. et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002; 51: 265-269
• 355 Christensen E, Crowe J, Doniach D. et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 1980; 78: 236-246
• 356 Younossi ZM, Bernstein D, Shiffman ML. et al. Diagnosis and Management of Primary Biliary Cholangitis. Am J Gastroenterol 2019; 114: 48-63
• 357 Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007; 194: 293-299
• 358 Chang PY, Lu SC, Su TC. et al. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res 2004; 45: 2116-2122
• 359 Ungprasert P, Wijarnpreecha K, Ahuja W. et al. Coronary artery disease in primary biliary cirrhosis: A systematic review and meta-analysis of observational studies. Hepatol Res 2015; 45: 1055-1061
• 360 Wang C, Zhao P, Liu W. Risk of incident coronary artery disease in patients with primary biliary cirrhosis. Int J Clin Exp Med 2014; 7: 2921-2924
• 361 Cash WJ, O’Neill S, O’Donnell ME. et al. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int 2013; 33: 1166-1174
• 362 Culp KS, Fleming CR, Duffy J. et al. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc 1982; 57: 365-370
• 363 Tsianos EV, Hoofnagle JH, Fox PC. et al. Sjogren’s syndrome in patients with primary biliary cirrhosis. Hepatology 1990; 11: 730-734
• 364 Kruszka P, O’Brian RJ. Diagnosis and management of Sjogren syndrome. Am Fam Physician 2009; 79: 465-70
• 365 Shen M, Zhang F, Zhang X. Primary biliary cirrhosis complicated with interstitial lung disease: a prospective study in 178 patients. J Clin Gastroenterol 2009; 43: 676-679
• 366 Liu B, Zhang FC, Zhang ZL. et al. Interstitial lung disease and Sjogren’s syndrome in primary biliary cirrhosis: a causal or casual association?. Clin Rheumatol 2008; 27: 1299-1306
• 367 Deng X, Li J, Hou S. et al. Prevalence and impact of Sjogren’s syndrome in primary biliary cholangitis: a systematic review and meta-analysis. Ann Hepatol 2022; 27: 100746
• 368 Ni P, Men R, Shen M. et al. Concomitant Sjogren’s Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis. Can J Gastroenterol Hepatol 2019; 2019: 7396870
• 369 Rigamonti C, Shand LM, Feudjo M. et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006; 55: 388-394
• 370 Myers RP, Swain MG, Lee SS. et al. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol 2013; 108: 933-941
• 371 Tsuda M, Moritoki Y, Lian ZX. et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 2012; 55: 512-521
• 372 Berg PA, Klein R. [Autoimmune hepatitis and overlap syndrome: diagnosis]. Praxis (Bern 1994) 2002; 91: 1339-1346
• 373 Gershwin ME, Selmi C, Worman HJ. et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005; 42: 1194-1202
• 374 Corpechot C, Chretien Y, Chazouilleres O. et al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol 2010; 53: 162-169
• 375 Uddenfeldt P, Danielsson A, Forssell A. et al. Features of Sjogren’s syndrome in patients with primary biliary cirrhosis. J Intern Med 1991; 230: 443-448
• 376 Inoue K, Hirohara J, Nakano T. et al. Prediction of prognosis of primary biliary cirrhosis in Japan. Liver 1995; 15: 70-77
• 377 Zheng B, Vincent C, Fritzler MJ. et al. Prevalence of Systemic Sclerosis in Primary Biliary Cholangitis Using the New ACR/EULAR Classification Criteria. J Rheumatol 2017; 44: 33-39
• 378 Dickey W, McMillan SA, Callender ME. High prevalence of celiac sprue among patients with primary biliary cirrhosis. J Clin Gastroenterol 1997; 25: 328-329
• 379 Kingham JG, Parker DR. The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. Gut 1998; 42: 120-122
• 380 Volta U, Rodrigo L, Granito A. et al. Celiac disease in autoimmune cholestatic liver disorders. Am J Gastroenterol 2002; 97: 2609-2613
• 381 Bardella MT, Quatrini M, Zuin M. et al. Screening patients with celiac disease for primary biliary cirrhosis and vice versa. Am J Gastroenterol 1997; 92: 1524-6
• 382 Mells GF, Pells G, Newton JL. et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology 2013; 58: 273-283
• 383 Untas A, Boujut E, Corpechot C. et al. Quality of life and illness perception in primary biliary cirrhosis: a controlled cross-sectional study. Clin Res Hepatol Gastroenterol 2015; 39: 52-58
• 384 Rudic JS, Poropat G, Krstic MN. et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012; 12: Cd000551
• 385 Poupon RE, Balkau B, Eschwege E. et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991; 324: 1548-1554
• 386 Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994; 330: 1342-1347
• 387 Poupon RE, Chretien Y, Poupon R. et al. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1993; 17: 599-604
• 388 Lammert C, Juran BD, Schlicht E. et al. Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients. J Gastroenterol 2014; 49: 1414-1420
• 389 Poupon RE, Lindor KD, Cauch-Dudek K. et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-890
• 390 Calmus Y, Poupon R. Ursodeoxycholic acid (UDCA) in the treatment of chronic cholestatic diseases. Biochimie 1991; 73: 1335-1338
• 391 Lindor KD, Therneau TM, Jorgensen RA. et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996; 110: 1515-1518
• 392 Battezzati PM, Podda M, Bianchi FB. et al. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC. J Hepatol 1993; 17: 332-338
• 393 Leuschner U, Fischer H, Kurtz W. et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989; 97: 1268-1274
• 394 Turner IB, Myszor M, Mitchison HC. et al. A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J Gastroenterol Hepatol 1994; 9: 162-168
• 395 Angulo P, Lindor KD, Therneau TM. et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999; 19: 115-121
• 396 Angulo P, Batts KP, Therneau TM. et al. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999; 29: 644-647
• 397 Batts KP, Jorgensen RA, Dickson ER. et al. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis. Am J Gastroenterol 1996; 91: 2314-2317
• 398 Harms MH, van Buuren HR, Corpechot C. et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol 2019; 71: 357-365
• 399 Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011; 55: 1361-1367
• 400 Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006; 130: 715-720
• 401 Harms MH, de Veer RC, Lammers WJ. et al. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut 2020; 69: 1502-1509
• 402 Lammers WJ, van Buuren HR, Hirschfield GM. et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014; 147: 1338-1349
• 403 Murillo Perez CF, Hirschfield GM, Corpechot C. et al. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Aliment Pharmacol Ther 2019; 50: 1127-1136
• 404 Carbone M, Mells GF, Pells G. et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013; 144: 560-569
• 405 Cheung AC, Lammers WJ, Murillo PerezCF. et al. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Clin Gastroenterol Hepatol 2019; 17: 2076-2084 e2
• 406 Zhang LN, Shi TY, Shi XH. et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology 2013; 58: 264-272
• 407 Kumagi T, Guindi M, Fischer SE. et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105: 2186-94
• 408 Murillo Perez CF, Harms MH, Lindor KD. et al. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. Am J Gastroenterol 2020;
• 409 Gatselis NK, Goet JC, Zachou K. et al. Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. Clin Gastroenterol Hepatol 2020; 18: 684-692
• 410 Hirschfield GM, Chazouilleres O, Cortez-Pinto H. et al. A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients. Expert Rev Gastroenterol Hepatol 2021; 15: 929-939
• 411 Nevens F, Andreone P, Mazzella G. et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med 2016; 375: 631-643
• 412 Trauner M, Nevens F, Shiffman ML. et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol 2019; 4: 445-453
• 413 Hirschfield GM, Mason A, Luketic V. et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015; 148: 751-761
• 414 Harms MH, Hirschfield GM, Floreani A. et al. Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. JHEP Rep 2021; 3: 100191
• 415 Bowlus CL, Pockros PJ, Kremer AE. et al. Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. Clin Gastroenterol Hepatol 2019;
• 416 Murillo Perez CF, Fisher H, Hiu S. et al. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls. Gastroenterology 2022; 163: 1630-1642
• 417 Eaton JE, Vuppalanchi R, Reddy R. et al. Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid. Hepatology 2020; 71: 1511-1514
• 418 Grigorian AY, Mardini HE, Corpechot C. et al. Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis. Clin Res Hepatol Gastroenterol 2015; 39: 296-306
• 419 Honda A, Ikegami T, Nakamuta M. et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2013; 57: 1931-1941
• 420 Honda A, Tanaka A, Kaneko T. et al. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis. Hepatology 2019; 70: 2035-2046
• 421 Tanaka A, Hirohara J, Nakanuma Y. et al. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA. J Gastroenterol 2015; 50: 675-682
• 422 Corpechot C, Chazouilleres O, Rousseau A. et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med 2018; 378: 2171-2181
• 423 Tanaka A, Hirohara J, Nakano T. et al. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J Hepatol 2021; 75: 565-571
• 424 Hosonuma K, Sato K, Yamazaki Y. et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol 2015; 110: 423-431
• 425 Reig A, Alvarez-Navascues C, Vergara M. et al. Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study. Am J Gastroenterol 2021; 116: 2250-2257
• 426 Reig A, Sese P, Pares A. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. Am J Gastroenterol 2018; 113: 49-55
• 427 Soret PA, Lam L, Carrat F. et al. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. Aliment Pharmacol Ther 2021; 53: 1138-1146
• 428 Smets L, Verbeek J, Korf H. et al. Improved Markers of Cholestatic Liver Injury in Patients With Primary Biliary Cholangitis Treated With Obeticholic Acid and Bezafibrate. Hepatology 2021; 73: 2598-2600
• 429 Duncan JS, Kennedy HJ, Triger DR. Treatment of pruritus due to chronic obstructive liver disease. Br Med J (Clin Res Ed) 1984; 289: 22
• 430 Xu C, Yue R, Lv X. et al. Efficacy and safety of pharmacological interventions for pruritus in primary biliary cholangitis: A systematic review and meta-analysis. Front Pharmacol 2022; 13: 835991
• 431 Shen N, Pan J, Miao H. et al. Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis. Ann Palliat Med 2021; 10: 7697-7705
• 432 de Vries E, Bolier R, Goet J. et al. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial. Gastroenterology 2021; 160: 734-743
• 433 Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94: 488-493
• 434 Bachs L, Pares A, Elena M. et al. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; 1: 574-576
• 435 Podesta A, Lopez P, Terg R. et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991; 36: 216-220
• 436 Tandon P, Rowe BH, Vandermeer B. et al. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007; 102: 1528-1536
• 437 Mayo MJ, Handem I, Saldana S. et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007; 45: 666-674
• 438 Stander S, Zeidler C, Augustin M. et al. S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus. J Dtsch Dermatol Ges 2022; 20: 1386-1402
• 439 Di Padova C, Tritapepe R, Rovagnati P. et al. Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol 1984; 6: 773-776
• 440 Rust C, Sauter GH, Oswald M. et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur J Clin Invest 2000; 30: 135-139
• 441 Bachs L, Pares A, Elena M. et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992; 102: 2077-2080
• 442 Webb GJ, Rahman SR, Levy C. et al. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. Aliment Pharmacol Ther 2018; 47: 1213-1219
• 443 Dull MM, Kremer AE. Evaluation and Management of Pruritus in Primary Biliary Cholangitis. Clin Liver Dis 2022; 26: 727-745
• 444 Mayo MJ, Pockros PJ, Jones D. et al. A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. Hepatol Commun 2019; 3: 365-381
• 445 Hegade VS, Kendrick SF, Dobbins RL. et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet 2017; 389: 1114-1123
• 446 Levy C, Kendrick S, Bowlus CL. et al. GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus. Clin Gastroenterol Hepatol 2022;
• 447 Murillo Perez CF, Goet JC, Lammers WJ. et al. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. Hepatology 2018; 67: 1920-1930
• 448 Lammers WJ, Hirschfield GM, Corpechot C. et al. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology 2015; 149: 1804-1812
• 449 Gerussi A, Bernasconi DP, O’Donnell SE. et al. Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. Clin Gastroenterol Hepatol 2021; 19: 1688-1697 e14
• 450 Takano K, Saeki C, Oikawa T. et al. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate. J Gastroenterol Hepatol 2020; 35: 663-672
• 451 Yang WH, Yu JH, Nakajima A. et al. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?. Clin Gastroenterol Hepatol 2004; 2: 1116-1122
• 452 Chen Q, Zhong R, Dong K. et al. The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China. Dig Liver Dis 2022; 54: 1094-1100
• 453 Haldar D, Janmohamed A, Plant T. et al. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis. Liver Int 2021; 41: 535-544
• 454 Degott C, Zafrani ES, Callard P. et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999; 29: 1007-1012
• 455 Corpechot C, Carrat F, Poupon R. et al. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002; 122: 652-658
• 456 Trivedi PJ, Bruns T, Cheung A. et al. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. J Hepatol 2014; 60: 1249-1258
• 457 Harms MH, Lammers WJ, Thorburn D. et al. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. Am J Gastroenterol 2018; 113: 254-264
• 458 Navasa M, Pares A, Bruguera M. et al. Portal hypertension in primary biliary cirrhosis. Relationship with histological features. J Hepatol 1987; 5: 292-298
• 459 Ali AH, Sinakos E, Silveira MG. et al. Varices in early histological stage primary biliary cirrhosis. J Clin Gastroenterol 45: e66-e71
• 460 Natarajan Y, Tansel A, Patel P. et al. Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci 2021; 66: 2439-2451
• 461 Trivedi PJ, Lammers WJ, van Buuren HR. et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut 2016; 65: 321-329
• 462 Chazouilleres O, Wendum D, Serfaty L. et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301
• 463 Boberg KM, Chapman RW, Hirschfield GM. et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54: 374-385
• 464 Bonder A, Retana A, Winston DM. et al. Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2011; 9: 609-612
• 465 Kanzler S, Bozkurt S, Herkel J. et al. [Presence of SLA/LP autoantibodies in patients with primary biliary cirrhosis as a marker for secondary autoimmune hepatitis (overlap syndrome)]. Dtsch Med Wochenschr 2001; 126: 450-456
• 466 Muratori P, Granito A, Pappas G. et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2009; 104: 1420-1425
• 467 Scheuer PJ. Ludwig Symposium on biliary disorders – part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. Mayo Clin Proc 1998; 73: 179-183
• 468 Poupon R, Chazouilleres O, Corpechot C. et al. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006; 44: 85-90
• 469 Silveira MG, Talwalkar JA, Angulo P. et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007; 102: 1244-1250
• 470 Neuhauser M, Bjornsson E, Treeprasertsuk S. et al. Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol 2010; 105: 345-53
• 471 Yang F, Wang Q, Wang Z. et al. The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis. Clin Rev Allergy Immunol 2016; 50: 114-123
• 472 Deneau M, Jensen MK, Holmen J. et al. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology 2013; 58: 1392-1400
• 473 Deneau MR, El-Matary W, Valentino PL. et al. The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration. Hepatology 2017; 66: 518-527
• 474 Miloh T, Arnon R, Shneider B. et al. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol 2009; 7: 239-245
• 475 Broome U, Olsson R, Loof L. et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-615
• 476 Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 31-39
• 477 Wiesner RH, Grambsch PM, Dickson ER. et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989; 10: 430-436
• 478 de Vries AB, Janse M, Blokzijl H. et al. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol 2015; 21: 1956-1971
• 479 Rasmussen HH, Fallingborg JF, Mortensen PB. et al. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn’s disease. Scand J Gastroenterol 1997; 32: 604-610
• 480 Gizard E, Ford AC, Bronowicki JP. et al. Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2014; 40: 3-15
• 481 Loftus EV Jr, Harewood GC, Loftus CG. et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-96
• 482 Aadland E, Schrumpf E, Fausa O. et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1987; 22: 655-664
• 483 Schrumpf E, Elgjo K, Fausa O. et al. Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol 1980; 15: 689-697
• 484 Sinakos E, Samuel S, Enders F. et al. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis 2013; 19: 1004-1009
• 485 Verdonk RC, Dijkstra G, Haagsma EB. et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant 2006; 6: 1422-1429
• 486 Faubion WA Jr, Loftus EV, Sandborn WJ. et al. Pediatric „PSC-IBD“: a descriptive report of associated inflammatory bowel disease among pediatric patients with psc. J Pediatr Gastroenterol Nutr 2001; 33: 296-300
• 487 Jørgensen KK, Grzyb K, Lundin KE. et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2012; 18: 536-545
• 488 Sørensen J, Nielsen OH, Andersson M. et al. Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population-based cohort study 1977-2011. Liver Int 2018; 38: 532-541
• 489 Wang MH, Mousa OY, Friton JJ. et al. Unique Phenotypic Characteristics and Clinical Course in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Multicenter US Experience. Inflamm Bowel Dis 2020; 26: 774-779
• 490 Lunder AK, Hov JR, Borthne A. et al. Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease. Gastroenterology 2016; 151: 660-669
• 491 Schramm C, Eaton J, Ringe KI. et al. Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. Hepatology 2017; 66: 1675-1688
• 492 Dusunceli E, Erden A, Erden I. et al. Primary sclerosing cholangitis: MR cholangiopancreatography and T2-weighted MR imaging findings. Diagn Interv Radiol 2005; 11: 213-218
• 493 Venkatesh SK, Welle CL, Miller FH. et al. Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group. Eur Radiol 2022; 32: 923-937
• 494 Arrive L, Ruiz A, El Mouhadi S. et al. MRI of cholangitis: traps and tips. Diagn Interv Imaging 2013; 94: 757-770
• 495 Schulze J, Lenzen H, Hinrichs JB. et al. An Imaging Biomarker for Assessing Hepatic Function in Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol 2019; 17: 192-199
• 496 Ringe KI, Grigoriadis A, Halibasic E. et al. Recommendations on the Use of Magnetic Resonance Imaging for Collaborative Multicenter Studies in Primary Sclerosing Cholangitis. Hepatology 2019; 69: 1358-1359
• 497 Gregorio GV, Portmann B, Karani J. et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33: 544-553
• 498 Milkiewicz P, Krawczyk M, Wunsch E. et al. Primary Sclerosing Cholangitis With Features of Autoimmune Hepatitis: Exploring the Global Variation in Management. Hepatol Commun 2020; 4: 399-408
• 499 Chazouilleres O, Beuers U, Bergquist A. et al. EASL Clinical Practice Guidelines on sclerosing cholangitis. Journal of Hepatology 2022; 77: 761-806
• 500 Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000; 33: 537-542
• 501 Hunter M, Loughrey MB, Gray M. et al. Evaluating distinctive features for early diagnosis of primary sclerosing cholangitis overlap syndrome in adults with autoimmune hepatitis. Ulster Med J 2011; 80: 15-18
• 502 Portmann B, Zen Y. Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology 2012; 60: 236-48
• 503 Boonstra K, Weersma RK, van Erpecum KJ. et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013; 58: 2045-2055
• 504 Ponsioen CY, Assis DN, Boberg KM. et al. Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. Gastroenterology 2021; 161: 1764-1775
• 505 de Vries E, Mazzetti M, Takkenberg B. et al. Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma. Liver Int 2020; 40: 3042-3050
• 506 Naess S, Bjornsson E, Anmarkrud JA. et al. Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. Liver Int 2014; 34: 1488-1495
• 507 Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002; 35: 1494-500
• 508 Weismüller TJ, Trivedi PJ, Bergquist A. et al. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology 2017; 152: 1975-1984
• 509 Chapman R, Fevery J, Kalloo A. et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-678
• 510 Trivedi PJ, Hirschfield GM. Review article: overlap syndromes and autoimmune liver disease. Aliment Pharmacol Ther 2012; 36: 517-533
• 511 Olsson R, Glaumann H, Almer S. et al. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med 2009; 20: 190-196
• 512 Floreani A, Rizzotto ER, Ferrara F. et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005; 100: 1516-1522
• 513 Zenouzi R, Lohse AW. Long-term outcome in PSC/AIH „overlap syndrome“: does immunosuppression also treat the PSC component?. J Hepatol 2014; 61: 1189-1191
• 514 Burak KW, Urbanski SJ, Swain MG. A case of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of autoimmune liver diseases. Dig Dis Sci 2001; 46: 2043-2047
• 515 Rubel LR, Seeff LB, Patel V. Primary biliary cirrhosis-primary sclerosing cholangitis overlap syndrome. Arch Pathol Lab Med 1984; 108: 360-361
• 516 Kerkar N, Miloh T. Sclerosing cholangitis: pediatric perspective. Curr Gastroenterol Rep 2010; 12: 195-202
• 517 Mieli-Vergani G, Vergani D. Autoimmune liver diseases in children – what is different from adulthood?. Best Pract Res Clin Gastroenterol 2011; 25: 783-795
• 518 Valentino PL, Wiggins S, Harney S. et al. The Natural History of Primary Sclerosing Cholangitis in Children: A Large Single-Center Longitudinal Cohort Study. J Pediatr Gastroenterol Nutr 2016; 63: 603-609
• 519 Tenca A, Farkkila M, Arola J. et al. Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis. United European Gastroenterol J 2016; 4: 562-569
• 520 Feldstein AE, Perrault J, El-Youssif M. et al. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003; 38: 210-217
• 521 Timmer A, Behrens R, Buderus S. et al. Childhood onset inflammatory bowel disease: predictors of delayed diagnosis from the CEDATA German-language pediatric inflammatory bowel disease registry. J Pediatr 2011; 158: 467-473
• 522 Ebbeson RL, Schreiber RA. Diagnosing autoimmune hepatitis in children: is the International Autoimmune Hepatitis Group scoring system useful?. Clin Gastroenterol Hepatol 2004; 2: 935-940
• 523 Rojas CP, Bodicharla R, Campuzano-Zuluaga G. et al. Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents. Fetal Pediatr Pathol 2014; 33: 202-209
• 524 Di Giorgio A, D’Adda A, Marseglia A. et al. Biliary features in liver histology of children with autoimmune liver disease. Hepatol Int 2019; 13: 510-518
• 525 Bowlus CL, Arrive L, Bergquist A. et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 2023; 77: 659-702
• 526 Ponsioen CY, Reitsma JB, Boberg KM. et al. Validation of a cholangiographic prognostic model in primary sclerosing cholangitis. Endoscopy 2010; 42: 742-747
• 527 Ruiz A, Lemoinne S, Carrat F. et al. Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. Hepatology 2014; 59: 242-250
• 528 Li J, Ye X, Wang J. et al. A comparative study of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound in the detection of intrahepatic lesion. Medicine (Baltimore) 2022; 101: e30482
• 529 Ricke J, Steffen IG, Bargellini I. et al. Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. JHEP Rep 2020; 2: 100173
• 530 Jhaveri K, Cleary S, Audet P. et al. Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid). Am J Roentgenol 2015; 204: 498-509
• 531 Aabakken L, Karlsen TH, Albert J. et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy 2017; 49: 588-608
• 532 Broomé U, Löfberg R, Lundqvist K. et al. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis Colon Rectum 1995; 38: 1301-1305
• 533 Broomé U, Löfberg R, Veress B. et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-1408
• 534 Zheng HH, Jiang XL. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. Eur J Gastroenterol Hepatol 2016; 28: 383-390
• 535 Soetikno RM, Lin OS, Heidenreich PA. et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: A meta-analysis. Gastrointestinal Endoscopy 2002; 56: 48-54
• 536 Trivedi PJ, Crothers H, Mytton J. et al. Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. Gastroenterology 2020; 159: 915-928
• 537 Chapman MH, Thorburn D, Hirschfield GM. et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut 2019; 68: 1356-1378
• 538 Harbord M, Annese V, Vavricka SR. et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis 2016; 10: 239-254
• 539 Lindor KD, Kowdley KV, Harrison ME. et al. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol 2015; 110: 646-659
• 540 El-Matary W, Guthery SL, Amir AZ. et al. Colorectal Dysplasia and Cancer in Pediatric-Onset Ulcerative Colitis Associated With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol 2021; 19: 1067-1070
• 541 Laborda TJ, Jensen MK, Kavan M. et al. Treatment of primary sclerosing cholangitis in children. World J Hepatol 2019; 11: 19-36
• 542 Olen O, Askling J, Sachs MC. et al. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. BMJ 2017; 358: j3951
• 543 Hensel KO, Kyrana E, Hadzic N. et al. Sclerosing Cholangitis in Pediatric Inflammatory Bowel Disease: Early Diagnosis and Management Affect Clinical Outcome. J Pediatr 2021; 238: 50-56
• 544 Deneau M, Adler DG, Schwartz JJ. et al. Cholangiocarcinoma in a 17-year-old boy with primary sclerosing cholangitis and inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 52: 617-620
• 545 Liu R, Cox K, Guthery SL. et al. Cholangiocarcinoma and high-grade dysplasia in young patients with primary sclerosing cholangitis. Dig Dis Sci 2014; 59: 2320-2324
• 546 Kucharzik T, Dignass A, Atreya R. et al. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2). Januar 2024 – AWMF-Registriernummer: 021-009. 2024 62. 769-858
• 547 Barnes EL, Holubar SD, Herfarth HH. Systematic Review and Meta-analysis of Outcomes After Ileal Pouch-anal Anastomosis in Primary Sclerosing Cholangitis and Ulcerative Colitis. J Crohns Colitis 2021; 15: 1272-1278
• 548 Nordenvall C, Olén O, Nilsson PJ. et al. Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients. Aliment Pharmacol Ther 2018; 47: 238-245
• 549 Peverelle M, Paleri S, Hughes J. et al. Activity of Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis Predicts Poorer Clinical Outcomes. Inflamm Bowel Dis 2020; 26: 1901-1908
• 550 Poropat G, Giljaca V, Stimac D. et al. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev 2011; 2011: CD003626
• 551 Deneau MR, Mack C, Abdou R. et al. Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis. Hepatol Commun 2018; 2: 1369-1378
• 552 Lindor KD, Kowdley KV, Luketic VA. et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-814
• 553 Beuers U, Trauner M, Jansen P. et al. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015; 62: S25-S37
• 554 Beuers U, Spengler U, Kruis W. et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992; 16: 707-714
• 555 Chazouilleres O, Poupon R, Capron JP. et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990; 11: 120-123
• 556 Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691-695
• 557 Olsson R, Boberg KM, de Muckadell OS. et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 1464-1472
• 558 Shi J, Li Z, Zeng X. et al. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res 2009; 39: 865-873
• 559 Triantos CK, Koukias NM, Nikolopoulou VN. et al. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther 2011; 34: 901-910
• 560 Al Mamari S, Djordjevic J, Halliday JS. et al. Improvement of serum alkaline phosphatase to < 1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2013; 58: 329-334
• 561 Lindstrom L, Hultcrantz R, Boberg KM. et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013; 11: 841-846
• 562 Stanich PP, Bjornsson E, Gossard AA. et al. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis 2011; 43: 309-313
• 563 Wunsch E, Trottier J, Milkiewicz M. et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology 2014; 60: 931-940
• 564 Cullen SN, Rust C, Fleming K. et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008; 48: 792-800
• 565 Harnois DM, Angulo P, Jorgensen RA. et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001; 96: 1558-1562
• 566 Mitchell SA, Bansi DS, Hunt N. et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121: 900-907
• 567 Gilger MA, Gann ME, Opekun AR. et al. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children. J Pediatr Gastroenterol Nutr 2000; 31: 136-141
• 568 Deneau M, Perito E, Ricciuto A. et al. Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course. J Pediatr 2019; 209: 92-96
• 569 Singh S, Khanna S, Pardi DS. et al. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2013; 19: 1631-1638
• 570 Hansen JD, Kumar S, Lo WK. et al. Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis. Dig Dis Sci 2013; 58: 3079-3087
• 571 Brandsaeter B, Isoniemi H, Broome U. et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004; 40: 815-822
• 572 Liu X, Wang H, Liu X. et al. Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis. Pharmacol Ther 2022; 237: 108163
• 573 Freedman BL, Danford CJ, Patwardhan V. et al. Treatment of Overlap Syndromes in Autoimmune Liver Disease: A Systematic Review and Meta-Analysis. J Clin Med 2020; 9
• 574 Boberg KM, Egeland T, Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol 2003; 38: 991-995
• 575 Mizuno S, Hirano K, Tada M. et al. Bezafibrate for the treatment of primary sclerosing cholangitis. J Gastroenterol 2010; 45: 758-762
• 576 Lemoinne S, Pares A, Reig A. et al. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience. Clin Res Hepatol Gastroenterol 2018; 42: 521-528
• 577 Hatami B, Mosala M, Hassani AH. et al. Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial. Pharmacol Res Perspect 2022; 10: e00984
• 578 Fickert P, Hirschfield GM, Denk G. et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol 2017; 67: 549-558
• 579 Trauner M, Gulamhusein A, Hameed B. et al. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology 2019; 70: 788-801
• 580 Kowdley KV, Vuppalanchi R, Levy C. et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J Hepatol 2020; 73: 94-101
• 581 Hirschfield GM, Chazouilleres O, Drenth JP. et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol 2019; 70: 483-493
• 582 Pohl J, Ring A, Stremmel W. et al. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2006; 18: 69-74
• 583 Shah A, Crawford D, Burger D. et al. Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Semin Liver Dis 2019; 39: 432-441
• 584 Kaya M, Bestas R, Bacalan F. et al. Microbial profile and antibiotic sensitivity pattern in bile cultures from endoscopic retrograde cholangiography patients. World J Gastroenterol 2012; 18: 3585-3589
• 585 Negm AA, Schott A, Vonberg RP. et al. Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis. Gastrointest Endosc 2010; 72: 284-291
• 586 Rerknimitr R, Fogel EL, Kalayci C. et al. Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis. Gastrointest Endosc 2002; 56: 885-889
• 587 Chandra S, Klair JS, Soota K. et al. Endoscopic Retrograde Cholangio-Pancreatography-Obtained Bile Culture Can Guide Antibiotic Therapy in Acute Cholangitis. Dig Dis 2019; 37: 155-160
• 588 European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol 2022; 77: 761-806
• 589 Bogatic D, Bryant RV, Lynch KD. et al. Systematic review: microbial manipulation as therapy for primary sclerosing cholangitis. Aliment Pharmacol Ther 2023; 57: 23-36
• 590 Hov JR, Karlsen TH. The Microbiome in Primary Sclerosing Cholangitis: Current Evidence and Potential Concepts. Semin Liver Dis 2017; 37: 314-331
• 591 Tabibian JH, O’Hara SP, Lindor KD. Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol 2014; 49: 901-908
• 592 Farkkila M, Karvonen AL, Nurmi H. et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004; 40: 1379-1386
• 593 Davies YK, Cox KM, Abdullah BA. et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008; 47: 61-67
• 594 Deneau MR, Mack C, Mogul D. et al. Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis. Hepatology 2021; 73: 1061-1073
• 595 Ferreira M, Ribeiro IB, de Moura DTH. et al. Stent versus Balloon Dilation for the Treatment of Dominant Strictures in Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis. Clin Endosc 2021; 54: 833-842
• 596 Dhaliwal AS, Naga Y, Ramai D. et al. A comparison of balloon- versus stent-based approach for dominant strictures in primary sclerosing cholangitis: a meta-analysis. Ann Gastroenterol 2022; 35: 307-316
• 597 Gotthardt DN, Rudolph G, Kloters-Plachky P. et al. Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment. Gastrointest Endosc 2010; 71: 527-534
• 598 Ponsioen CY, Arnelo U, Bergquist A. et al. No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. Gastroenterology 2018; 155: 752-759
• 599 Faigel DO, Ginsberg GG, Kochman ML. Innovative use of the Soehendra stent retriever for biliary stricture recannalization. Gastrointest Endosc 1996; 44: 635
• 600 Kaya M, Petersen BT, Angulo P. et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001; 96: 1059-1066
• 601 van Milligen deWit AW, Rauws EA, van Bracht J. et al. Lack of complications following short-term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1997; 46: 344-347
• 602 Rupp C, Hippchen T, Bruckner T. et al. Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis. Gut 2019; 68: 2170-2178
• 603 Alkhatib AA, Hilden K, Adler DG. Comorbidities, sphincterotomy, and balloon dilation predict post-ERCP adverse events in PSC patients: operator experience is protective. Dig Dis Sci 2011; 56: 3685-8
• 604 Etzel JP, Eng SC, Ko CW. et al. Complications after ERCP in patients with primary sclerosing cholangitis. Gastrointest Endosc 2008; 67: 643-648
• 605 Gluck M, Cantone NR, Brandabur JJ. et al. A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J Clin Gastroenterol 2008; 42: 1032-1039
• 606 Ismail S, Kylanpaa L, Mustonen H. et al. Risk factors for complications of ERCP in primary sclerosing cholangitis. Endoscopy 2012; 44: 1133-1138
• 607 Navaneethan U, Jegadeesan R, Nayak S. et al. ERCP-related adverse events in patients with primary sclerosing cholangitis. Gastrointest Endosc 2015; 81: 410-419
• 608 Peiseler M, Reiners D, Pinnschmidt HO. et al. Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis. PLoS One 2018; 13: e0202686
• 609 van den Hazel SJ, Wolfhagen EH, van Buuren HR. et al. Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group. Endoscopy 2000; 32: 779-782
• 610 Bangarulingam SY, Gossard AA, Petersen BT. et al. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol 2009; 104: 855-860
• 611 Cotton PB, Connor P, Rawls E. et al. Infection after ERCP, and antibiotic prophylaxis: a sequential quality-improvement approach over 11 years. Gastrointest Endosc 2008; 67: 471-475
• 612 van den Hazel SJ, Speelman P, Dankert J. et al. Piperacillin to prevent cholangitis after endoscopic retrograde cholangiopancreatography. A randomized, controlled trial. Ann Intern Med 1996; 125: 442-447
• 613 Brand M, Bizos D, O’Farrell PJr. Antibiotic prophylaxis for patients undergoing elective endoscopic retrograde cholangiopancreatography. Cochrane Database Syst Rev 2010; CD007345
• 614 de Franchis R, Bosch J, Garcia-Tsao G. et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol 2022; 76: 959-974
• 615 de Vries EMG, Farkkila M, Milkiewicz P. et al. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. Liver Int 2017; 37: 1554-1561
• 616 Fossdal G, Mjelle AB, Wiencke K. et al. Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF. JHEP Rep 2021; 3: 100328
• 617 Deneau MR, Valentino PL, Mack C. et al. Assessing the Validity of Adult-derived Prognostic Models for Primary Sclerosing Cholangitis Outcomes in Children. J Pediatr Gastroenterol Nutr 2020; 70: e12-e17
• 618 Deneau MR, Mack C, Perito ER. et al. The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) Index: A Prognostic Tool for Children. Hepatology 2021; 73: 1074-1087
• 619 Lee CK, Mitchell PD, Raza R. et al. Validation of Transient Elastography Cut Points to Assess Advanced Liver Fibrosis in Children and Young Adults: The Boston Children’s Hospital Experience. J Pediatr 2018; 198: 84-89
• 620 Eaton JE, Welle CL, Bakhshi Z. et al. Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis. Hepatology 2021; 73: 1868-1881
• 621 Charatcharoenwitthaya P, Enders FB, Halling KC. et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008; 48: 1106-1117
• 622 Villard C, Friis-Liby I, Rorsman F. et al. Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis. J Hepatol 2022;
• 623 Ali AH, Tabibian JH, Nasser-Ghodsi N. et al. Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. Hepatology 2018; 67: 2338-2351
• 624 Bergquist A, Weismuller TJ, Levy C. et al. Impact on follow-up strategies in patients with primary sclerosing cholangitis. Liver Int 2023; 43: 127-138
• 625 Boonstra K, Weersma RK, van Erpecum KJ. et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013; 58: 2045-2055
• 626 Erichsen R, Olen O, Sachs MC. et al. Hepatobiliary Cancer Risk in Patients with Inflammatory Bowel Disease: A Scandinavian Population-Based Cohort Study. Cancer Epidemiol Biomarkers Prev 2021; 30: 886-894
• 627 Harnois DM, Gores GJ, Ludwig J. et al. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer?. J Hepatol 1997; 27: 512-516
• 628 Zenouzi R, Weismuller TJ, Hubener P. et al. Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis. Clin Gastroenterol Hepatol 2014; 12: 1733-1738
• 629 Bergquist A, Ekbom A, Olsson R. et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321-327
• 630 de Valle MB, Bjornsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int 2012; 32: 441-448
• 631 Bowlus CL, Lim JK, Lindor KD. AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. Clin Gastroenterol Hepatol 2019; 17: 2416-2422
• 632 Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011; 54: 1842-1852
• 633 Nair AV, Macdonald DB, Kelly EM. et al. Utility of MRCP in surveillance of primary sclerosing cholangitis associated hepatobiliary malignancy: 15 year experience at a single institution in Ontario, Canada. Clin Imaging 2022; 81: 47-53
• 634 Trikudanathan G, Navaneethan U, Njei B. et al. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014; 79: 783-789
• 635 Njei B, McCarty TR, Varadarajulu S. et al. Systematic review with meta-analysis: endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Aliment Pharmacol Ther 2016; 44: 1139-1151
• 636 Majeed A, Castedal M, Arnelo U. et al. Optimizing the detection of biliary dysplasia in primary sclerosing cholangitis before liver transplantation. Scand J Gastroenterol 2018; 53: 56-63
• 637 Navaneethan U, Njei B, Venkatesh PG. et al. Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014; 79: 943-950
• 638 Chapman MH, Webster GJ, Bannoo S. et al. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol 2012; 24: 1051-1058
• 639 Fevery J, Verslype C, Lai G. et al. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 2007; 52: 3123-3135
• 640 Boyd S, Tenca A, Jokelainen K. et al. Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia. Endoscopy 2016; 48: 432-439
• 641 von Seth E, Ouchterlony H, Dobra K. et al. Diagnostic performance of a stepwise cytological algorithm for biliary malignancy in primary sclerosing cholangitis. Liver Int 2019; 39: 382-388
• 642 Andresen K, Boberg KM, Vedeld HM. et al. Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma. Hepatology 2015; 61: 1651-1659
• 643 Yang JD, Ghoz H, Aboelsoud MM. et al. DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma. Hepatol Commun 2021; 5: 1448-1459
• 644 Porner D, Kaczmarek DJ, Heling D. et al. Transpapillary tissue sampling of biliary strictures: balloon dilatation prior to forceps biopsy improves sensitivity and accuracy. Sci Rep 2020; 10: 17423
• 645 Nguyen NQ, Schoeman MN, Ruszkiewicz A. Clinical utility of EUS before cholangioscopy in the evaluation of difficult biliary strictures. Gastrointest Endosc 2013; 78: 868-874
• 646 Han S, Kahaleh M, Sharaiha RZ. et al. Probe-based confocal laser endomicroscopy in the evaluation of dominant strictures in patients with primary sclerosing cholangitis: results of a U.S. multicenter prospective trial. Gastrointest Endosc 2021; 94: 569-576
• 647 Heif M, Yen RD, Shah RJ. ERCP with probe-based confocal laser endomicroscopy for the evaluation of dominant biliary stenoses in primary sclerosing cholangitis patients. Dig Dis Sci 2013; 58: 2068-2074
• 648 Hultcrantz R, Olsson R, Danielsson A. et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999; 30: 669-673
• 649 Venkatesh PG, Navaneethan U, Shen B. et al. Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci 2013; 58: 850-857
• 650 Levy C, Lymp J, Angulo P. et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005; 50: 1734-1740
• 651 Sinakos E, Saenger AK, Keach J. et al. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol 2011; 9: 434-9 e1
• 652 Ramage JK, Donaghy A, Farrant JM. et al. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108: 865-869
• 653 Wannhoff A, Brune M, Knierim J. et al. Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2019; 49: 769-778
• 654 Wannhoff A, Rupp C, Friedrich K. et al. Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol 2015; 13: 2372-2379
• 655 Parra-Robert M, Santos VM, Canis SM. et al. Relationship Between CA 19.9 and the Lewis Phenotype: Options to Improve Diagnostic Efficiency. Anticancer Res 2018; 38: 5883-5888
• 656 Wannhoff A, Hov JR, Folseraas T. et al. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 2013; 59: 1278-1284
• 657 Vogel A, Bridgewater J, Edeline J. et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 127-140
• 658 Siqueira E, Schoen RE, Silverman W. et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc 2002; 56: 40-47
• 659 Wannhoff A, Folseraas T, Brune M. et al. A common genetic variant of fucosyltransferase 2 correlates with serum carcinoembryonic antigen levels and affects cancer screening in patients with primary sclerosing cholangitis. United European Gastroenterol J 2016; 4: 84-91
• 660 Eaton JE, Thackeray EW, Lindor KD. Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol 2012; 107: 431-9
• 661 Buckles DC, Lindor KD, Larusso NF. et al. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 2002; 97: 1138-1142
• 662 Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 2008; 48: 598-605
• 663 Lewis JT, Talwalkar JA, Rosen CB. et al. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol 2007; 31: 907-913
• 664 Kronsten V, Fitzpatrick E, Baker A. Management of cholestatic pruritus in paediatric patients with alagille syndrome: the King’s College Hospital experience. J Pediatr Gastroenterol Nutr 2013; 57: 149-54
• 665 Baumann U, Sturm E, Lacaille F. et al. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study. Clin Res Hepatol Gastroenterol 2021; 45: 101751
• 666 Thompson RJ, Arnell H, Artan R. et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2022; 7: 830-842
• 667 Kamath BM, Goldstein A, Howard R. et al. Maralixibat Treatment Response in Alagille Syndrome is Associated with Improved Health-Related Quality of Life. J Pediatr 2023; 252: 68-75
• 668 Kamath BM, Abetz-Webb L, Kennedy C. et al. Development of a Novel Tool to Assess the Impact of Itching in Pediatric Cholestasis. Patient 2018; 11: 69-82
• 669 Jorgensen RA, Lindor KD, Sartin JS. et al. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol 1995; 20: 215-219
• 670 Radhakrishnan KR, Alkhouri N, Worley S. et al. Autoimmune hepatitis in children--impact of cirrhosis at presentation on natural history and long-term outcome. Dig Liver Dis 2010; 42: 724-8
• 671 Send SR. Nutritional Management of Cholestasis. Clin Liver Dis (Hoboken) 2020; 15: 9-12
• 672 Löhr JM, Vujasinovic M, Rosendahl J. et al. IgG4-related diseases of the digestive tract. Nat Rev Gastroenterol Hepatol 2022; 19: 185-197
• 673 Löhr JM, Beuers U, Vujasinovic M. et al. European Guideline on IgG4-related digestive disease – UEG and SGF evidence-based recommendations. United European Gastroenterol J 2020; 8: 637-666
• 674 de Buy Wenniger LJ, Culver EL, Beuers U. Exposure to occupational antigens might predispose to IgG4-related disease. Hepatology 2014; 60: 1453-1454
• 675 Hubers LM, Schuurman AR, Buijs J. et al. Blue-collar work is a risk factor for developing IgG4-related disease of the biliary tract and pancreas. JHEP Rep 2021; 3: 100385
• 676 Katz G, Stone JH. Clinical Perspectives on IgG4-Related Disease and Its Classification. Annu Rev Med 2022; 73: 545-562
• 677 Herta T, Verheij J, Beuers U. [IgG4-associated cholangitis – clinical presentation of an overlooked disease entity]. Internist (Berl) 2018; 59: 560-566
• 678 Ghazale A, Chari ST, Zhang L. et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134: 706-15
• 679 Erdogan D, Kloek JJ, ten KateFJ. et al. Immunoglobulin G4-related sclerosing cholangitis in patients resected for presumed malignant bile duct strictures. Br J Surg 2008; 95: 727-734
• 680 Roos E, Hubers LM, Coelen RJS. et al. IgG4-Associated Cholangitis in Patients Resected for Presumed Perihilar Cholangiocarcinoma: a 30-Year Tertiary Care Experience. Am J Gastroenterol 2018; 113: 765-772
• 681 El Jamaly H, Eslick GD, Weltman M. Systematic review with meta-analysis: autoimmune hepatitis in pregnancy. Scand J Gastroenterol 2021; 56: 1194-1204
• 682 Si T, Huang Z, Hegarty R. et al. Systematic review with meta-analysis: outcomes of pregnancy in patients with autoimmune hepatitis. Aliment Pharmacol Ther 2022; 55: 1368-1378
• 683 Sharma R, Simon TG, Stephansson O. et al. Pregnancy Outcomes in Women With Autoimmune Hepatitis – A Nationwide Population-based Cohort Study With Histopathology. Clin Gastroenterol Hepatol 2023; 21: 103-114
• 684 Alami Z, Agier MS, Ahid S. et al. Pregnancy outcome following in utero exposure to azathioprine: A French comparative observational study. Therapie 2018; 73: 199-207
• 685 Goldstein LH, Dolinsky G, Greenberg R. et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 2007; 79: 696-701
• 686 Matarazzo L, Nastasio S, Sciveres M. et al. Pregnancy outcome in women with childhood onset autoimmune hepatitis and autoimmune sclerosing cholangitis on long-term immunosuppressive treatment. Eur J Obstet Gynecol Reprod Biol 2022; 268: 7-11
• 687 Westbrook RH, Yeoman AD, Kriese S. et al. Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun 2012; 38: 239-244
• 688 Llovet LP, Horta D, Eliz MG. et al. Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2019; 17: 2819-2821
• 689 Fischer SE, de Vries ES, Tushuizen ME. et al. Importance of complete response for outcomes of pregnancy in patients with autoimmune hepatitis. Liver Int 2023;
• 690 Wang CW, Grab J, Tana MM. et al. Outcomes of pregnancy in autoimmune hepatitis: A population-based study. Hepatology 2022; 75: 5-12
• 691 Stokkeland K, Ludvigsson JF, Hultcrantz R. et al. Increased risk of preterm birth in women with autoimmune hepatitis – a nationwide cohort study. Liver Int 2016; 36: 76-83
• 692 Gronbaek L, Vilstrup H, Jepsen P. Pregnancy and birth outcomes in a Danish nationwide cohort of women with autoimmune hepatitis and matched population controls. Aliment Pharmacol Ther 2018; 48: 655-663
• 693 Gotestam SkorpenC, Hoeltzenbein M, Tincani A. et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75: 795-810
• 694 Pisoni CN, D’Cruz DP. The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf 2008; 7: 219-222
• 695 Wiest I, Roig A, Antoni C. et al. Safety and efficacy of budesonide during pregnancy in women with autoimmune hepatitis. J Gastrointestin Liver Dis 2022; 31: 256-257
• 696 Heneghan MA, Norris SM, O’Grady JG. et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001; 48: 97-102
• 697 Buchel E, Van Steenbergen W, Nevens F. et al. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol 2002; 97: 3160-3165
• 698 Knolle P, Mayet W, Lohse AW. et al. Complete congenital heart block in autoimmune hepatitis (SLA-positive). J Hepatol 1994; 21: 224-226
• 699 Schramm C, Herkel J, Beuers U. et al. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006; 101: 556-560
• 700 Olsen K, Hodson J, Ronca V. et al. Type 2 Autoimmune Hepatitis and Nonadherence to Medication Correlate With Premature Birth and Risk of Postpartum Flare. Hepatol Commun 2021; 5: 1252-1264
• 701 Bozward AG, Wootton GE, Podstawka O. et al. Autoimmune Hepatitis: Tolerogenic Immunological State During Pregnancy and Immune Escape in Post-partum. Front Immunol 2020; 11: 591380
• 702 Singh M, Qualie J, Currie A. et al. Is breastfeeding safe with azathioprine?. Obstet Med 2011; 4: 104-107
• 703 Christensen LA, Dahlerup JF, Nielsen MJ. et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008; 28: 1209-1213
• 704 Ryu RJ, Easterling TR, Caritis SN. et al. Prednisone Pharmacokinetics During Pregnancy and Lactation. J Clin Pharmacol 2018; 58: 1223-1232
• 705 El Jamaly H, Eslick GD, Weltman M. Primary biliary cholangitis in pregnancy: A systematic review with meta-analysis. Hepatobiliary Pancreat Dis Int 2022; 21: 218-225
• 706 Floreani A, Infantolino C, Franceschet I. et al. Pregnancy and primary biliary cirrhosis: a case-control study. Clinical reviews in allergy & immunology 2015; 48: 236-242
• 707 Parikh-Patel A, Gold E, Utts J. et al. The association between gravidity and primary biliary cirrhosis. Ann Epidemiol 2002; 12: 264-272
• 708 Trivedi PJ, Kumagi T, Al-Harthy N. et al. Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2014; 12: 1179-1185
• 709 Cauldwell M, Mackie FL, Steer PJ. et al. Pregnancy outcomes in women with primary biliary cholangitis and primary sclerosing cholangitis: a retrospective cohort study. BJOG 2020; 127: 876-884
• 710 Efe C, Kahramanoglu-Aksoy E, Yilmaz B. et al. Pregnancy in women with primary biliary cirrhosis. Autoimmun Rev 2014; 13: 931-5
• 711 Poupon R, Chretien Y, Chazouilleres O. et al. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. J Hepatol 2005; 42: 418-419
• 712 de Vries E, Beuers U. Ursodeoxycholic acid in pregnancy?. J Hepatol 2019; 71: 1237-1245
• 713 Vitek L, Zelenkova M, Bruha R. Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis. Dig Liver Dis 2010; 42: 911-912
• 714 Wellge BE, Sterneck M, Teufel A. et al. Pregnancy in primary sclerosing cholangitis. Gut 2011; 60: 1117-1121
• 715 Wronka KM, Bik E, Milkiewicz P. Outcome of pregnancy in patients with primary sclerosing cholangitis. Dig Liver Dis 2022; 54: 509-514
• 716 Ludvigsson JF, Bergquist A, Ajne G. et al. A population-based cohort study of pregnancy outcomes among women with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2014; 12: 95-100
• 717 Janczewska I, Olsson R, Hultcrantz R. et al. Pregnancy in patients with primary sclerosing cholangitis. Liver 1996; 16: 326-330
• 718 Bookstaver PB, Bland CM, Griffin B. et al. A Review of Antibiotic Use in Pregnancy. Pharmacotherapy 2015; 35: 1052-1062
• 719 Burtin P, Taddio A, Ariburnu O. et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995; 172: 525-529
• 720 Klebanoff MA, Carey JC, Hauth JC. et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001; 345: 487-493
• 721 Tiboni GM, Marotta F, Castigliego AP. Teratogenic effects in mouse fetuses subjected to the concurrent in utero exposure to miconazole and metronidazole. Reprod Toxicol 2008; 26: 254-261
• 722 Yefet E, Schwartz N, Chazan B. et al. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis. BJOG 2018; 125: 1069-1076
• 723 Oto A, Ernst R, Ghulmiyyah L. et al. The role of MR cholangiopancreatography in the evaluation of pregnant patients with acute pancreaticobiliary disease. Br J Radiol 2009; 82: 279-285
• 724 Torloni MR, Vedmedovska N, Merialdi M. et al. Safety of ultrasonography in pregnancy: WHO systematic review of the literature and meta-analysis. Ultrasound Obstet Gynecol 2009; 33: 599-608
• 725 Ray JG, Vermeulen MJ, Bharatha A. et al. Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. JAMA 2016; 316: 952-961
• 726 Committee ASoP, Shergill AK, Ben-Menachem T. et al. Guidelines for endoscopy in pregnant and lactating women. Gastrointest Endosc 2012; 76: 18-24
• 727 Dumonceau JM, Garcia-Fernandez FJ, Verdun FR. et al. Radiation protection in digestive endoscopy: European Society of Digestive Endoscopy (ESGE) guideline. Endoscopy 2012; 44: 408-421
• 728 Azab M, Bharadwaj S, Jayaraj M. et al. Safety of endoscopic retrograde cholangiopancreatography (ERCP) in pregnancy: A systematic review and meta-analysis. Saudi J Gastroenterol 2019; 25: 341-354
• 729 Tang SJ, Mayo MJ, Rodriguez-Frias E. et al. Safety and utility of ERCP during pregnancy. Gastrointest Endosc 2009; 69: 453-461
• 730 Inamdar S, Berzin TM, Sejpal DV. et al. Pregnancy is a Risk Factor for Pancreatitis After Endoscopic Retrograde Cholangiopancreatography in a National Cohort Study. Clin Gastroenterol Hepatol 2016; 14: 107-114
• 731 Laudanno O, Garrido J, Ahumaran G. et al. Long-term follow-up after fetal radiation exposure during endoscopic retrograde cholangiopancreatography. Endosc Int Open 2020; 8: E1909-E1914
• 732 van der Slink LL, Scholten I, van Etten-Jamaludin FS. et al. Pregnancy in women with liver cirrhosis is associated with increased risk for complications: A systematic review and meta-analysis of the literature. Bjog 2022; 129: 1644-1652
• 733 Gerbes AL, Labenz J, Appenrodt B. et al. Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“. AWMF-Nr.: 021-017. 2019 57. 611-680
• 734 Wehrmann T, Riphaus A, Eckardt AJ. et al. Aktualisierte S3-Leitlinie „Sedierung in der gastrointestinalen Endoskopie“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Juni 2023 – AWMF-Registernummer: 021/014. 2023 61. 1246-1301
• 735 Shaheen AA, Myers RP. The outcomes of pregnancy in patients with cirrhosis: a population-based study. Liver Int 2010; 30: 275-283
• 736 Sarkar M, Brady CW, Fleckenstein J. et al. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 73: 318-365
• 737 Mullin M, Djerboua M, Sarkar M. et al. Pregnancy Is Not Associated with an Increased Risk of Decompensation, Transplant, or Death in Compensated Cirrhosis. Int J Hepatol 2022; 2022: 9985226
• 738 Flemming JA, Mullin M, Lu J. et al. Outcomes of Pregnant Women With Cirrhosis and Their Infants in a Population-Based Study. Gastroenterology 2020; 159: 1752-1762
• 739 Gala AR, Surapaneni T, Aziz N. et al. A Review of Outcomes in Pregnant Women with Portal Hypertension. J Obstet Gynaecol India 2018; 68: 447-451
• 740 Britton RC. Pregnancy and esophageal varices. Am J Surg 1982; 143: 421-425
• 741 communication UFaDAFds. FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. 2016 https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm Accessed February 10, 2017.
• 742 Kohli R, Cortes M, Heaton ND. et al. Liver transplantation in children: state of the art and future perspectives. Arch Dis Child 2018; 103: 192-198
• 743 Liberal R, Krawitt EL, Vierling JM. et al. Cutting edge issues in autoimmune hepatitis. Journal of Autoimmunity 2016; 75: 6-19
• 744 Heinemann M, Adam R, Berenguer M. et al. Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry. Liver Transpl 2020; 26: 866-877
• 745 Chen C, Ke R, Yang F. et al. Risk factors for recurrent autoimmune liver diseases after liver transplantation: A meta-analysis. Medicine (Baltimore) 2020; 99: e20205
• 746 Pedersen MR, Greenan G, Arora S. et al. Ursodeoxycholic Acid Decreases Incidence of Primary Biliary Cholangitis and Biliary Complications After Liver Transplantation: A Meta-Analysis. Liver Transpl 2021; 27: 866-875
• 747 Montano-Loza AJ, Ronca V, Ebadi M. et al. Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. J Hepatol 2022; 77: 84-97
• 748 Corpechot C, Chazouillères O, Belnou P. et al. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. J Hepatol 2020; 73: 559-565
• 749 Alabraba E, Nightingale P, Gunson B. et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009; 15: 330-340
• 750 Graziadei IW, Wiesner RH, Marotta PJ. et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999; 30: 1121-1127
• 751 Campsen J, Zimmerman MA, Trotter JF. et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl 2008; 14: 181-5
• 752 Rowe IA, Webb K, Gunson BK. et al. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008; 21: 459-465
• 753 Cholongitas E, Shusang V, Papatheodoridis GV. et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008; 14: 138-143
• 754 Fosby B, Karlsen TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012; 18: 1-15
• 755 Hildebrand T, Pannicke N, Dechene A. et al. Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis. Liver Transpl 2016; 22: 42-52
• 756 Ravikumar R, Tsochatzis E, Jose S. et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol 2015; 63: 1139-1146
• 757 Czaja AJ. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Dig Dis Sci 2012; 57: 2248-2266
• 758 Manns MP, Czaja AJ, Gorham JD. et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-2213
• 759 Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol 2014; 60: 210-223
• 760 Heinemann M, Liwinski T, Adam R. et al. Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the European Liver Transplant Registry. Am J Transplant 2022; 22: 626-633
• 761 Gordon FD, Goldberg DS, Goodrich NP. et al. Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients. Liver Transpl 2016; 22: 1214-1222
• 762 Aravinthan AD, Doyle AC, Issachar A. et al. First-Degree Living-Related Donor Liver Transplantation in Autoimmune Liver Diseases. Am J Transplant 2016; 16: 3512-3521
• 763 Bergquist A, Lindberg G, Saarinen S. et al. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol 2005; 42: 252-256
• 764 Li X, Peng J, Ouyang R. et al. Risk factors for recurrent primary biliary cirrhosis after liver transplantation: A systematic review and meta-analysis. Dig Liver Dis 2021; 53: 309-317
• 765 Charatcharoenwitthaya P, Pimentel S, Talwalkar JA. et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007; 13: 1236-1245
• 766 Liermann Garcia RF, Evangelista Garcia C, McMaster P. et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001; 33: 22-27
• 767 Montano-Loza AJ, Hansen BE, Corpechot C. et al. Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. Gastroenterology 2019; 156: 96-107 e1
• 768 Montano-Loza AJ, Wasilenko S, Bintner J. et al. Cyclosporine A protects against primary biliary cirrhosis recurrence after liver transplantation. Am J Transplant 2010; 10: 852-858
• 769 Silveira MG, Talwalkar JA, Lindor KD. et al. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant 2010; 10: 720-726
• 770 Montano-Loza AJ, Mason AL. Recurrence of primary biliary cholangitis after liver transplantation: A Japanese perspective. Hepatol Commun 2017; 1: 391-393
• 771 Kogiso T, Egawa H, Teramukai S. et al. Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: A Japanese multicenter retrospective study. Hepatol Commun 2017; 1: 394-405
• 772 Jacob DA, Neumann UP, Bahra M. et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant 2006; 20: 211-20
• 773 Sanchez EQ, Levy MF, Goldstein RM. et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation 2003; 76: 1583-1588
• 774 Manousou P, Arvaniti V, Tsochatzis E. et al. Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity. Liver Transpl 2010; 16: 64-73
• 775 Krishnamoorthy TL, Miezynska-Kurtycz J, Hodson J. et al. Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent disease. Liver Transpl 2016; 22: 34-41
• 776 Satapathy SK, Vanatta JM, Helmick RA. et al. Outcome of Liver Transplant Recipients With Revascularized Coronary Artery Disease: A Comparative Analysis With and Without Cardiovascular Risk Factors. Transplantation 2017; 101: 793-803
• 777 Gonzalez-Koch A, Czaja AJ, Carpenter HA. et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001; 7: 302-310
• 778 Wright HL, Bou-Abboud CF, Hassanein T. et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 1992; 53: 136-139
• 779 Montano-Loza AJ, Mason AL, Ma M. et al. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl 2009; 15: 1254-1261
• 780 Heffron TG, Smallwood GA, Oakley B. et al. Autoimmune hepatitis following liver transplantation: relationship to recurrent disease and steroid weaning. Transplant Proc 2002; 34: 3311-3312
• 781 Campsen J, Zimmerman MA, Trotter JF. et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl 2008; 14: 1281-1286
• 782 Milkiewicz P, Hubscher SG, Skiba G. et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999; 68: 253-256
• 783 Gotz G, Neuhaus R, Bechstein WO. et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplant Proc 1999; 31: 430-431
• 784 Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006; 12: 1813-1824
• 785 Molmenti EP, Netto GJ, Murray NG. et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl 2002; 8: 519-526
• 786 Vogel A, Heinrich E, Bahr MJ. et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004; 18: 62-69
• 787 Junge G, Neuhaus R, Schewior L. et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. Transplant Proc 2005; 37: 1695-1696
• 788 Vergani D, Mieli-Vergani G. Autoimmunity after liver transplantation. Hepatology 2002; 36: 271-276
• 789 Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis 2009; 29: 286-296
• 790 Chapman R, Fevery J, Kalloo A. et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-678
• 791 Li KK, Neuberger J. Recurrent nonviral liver disease following liver transplantation. Expert Rev Gastroenterol Hepatol 2009; 3: 257-68
• 792 Pandanaboyana S, Bell R, Bartlett AJ. et al. Meta-analysis of Duct-to-duct versus Roux-en-Y biliary reconstruction following liver transplantation for primary sclerosing cholangitis. Transpl Int 2015; 28: 485-491
• 793 Esfeh JM, Eghtesad B, Hodgkinson P. et al. Duct-to-duct biliary reconstruction in patients with primary sclerosing cholangitis undergoing liver transplantation. HPB (Oxford) 2011; 13: 651-655
• 794 Goss JA, Shackleton CR, Farmer DG. et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997; 225: 472-481
• 795 Sutton ME, Bense RD, Lisman T. et al. Duct-to-duct reconstruction in liver transplantation for primary sclerosing cholangitis is associated with fewer biliary complications in comparison with hepaticojejunostomy. Liver Transpl 2014; 20: 457-463
• 796 Wells MM, Croome KP, Boyce E. et al. Roux-en-Y choledochojejunostomy versus duct-to-duct biliary anastomosis in liver transplantation for primary sclerosing cholangitis: a meta-analysis. Transplant Proc 2013; 45: 2263-2271
• 797 Singh S, Edakkanambeth Varayil J, Loftus EV Jr. et al. Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Transpl 2013; 19: 1361-1369
• 798 Jorgensen KK, Lindstrom L, Cvancarova M. et al. Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. Scand J Gastroenterol 2012; 47: 1021-1029
• 799 Sturm A, Atreya R, Bettenworth D. et al. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2022; 60: 332-418
• 800 Hanouneh IA, Macaron C, Lopez R. et al. Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis 2012; 18: 269-274
• 801 Chai PF, Lee WS, Brown RM. et al. Childhood autoimmune liver disease: indications and outcome of liver transplantation. J Pediatr Gastroenterol Nutr 2010; 50: 295-302
• 802 Martin SR, Alvarez F, Anand R. et al. Outcomes in children who underwent transplantation for autoimmune hepatitis. Liver Transpl 2011; 17: 393-401
• 803 Floreani A, Liberal R, Vergani D. et al. Autoimmune hepatitis: Contrasts and comparisons in children and adults – a comprehensive review. J Autoimmun 2013; 46: 7-16
• 804 Miloh T, Anand R, Yin W. et al. Pediatric liver transplantation for primary sclerosing cholangitis. Liver Transpl 2011; 17: 925-933
• 805 Schramm C, Bubenheim M, Adam R. et al. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl 2010; 16: 461-469
• 806 Dehghani SM, Haghighat M, Imanieh MH. et al. Autoimmune hepatitis in children: experiences in a tertiary center. Iran J Pediatr 2013; 23: 302-308
• 807 Venkat VL, Ranganathan S, Mazariegos GV. et al. Recurrence of primary sclerosing cholangitis in pediatric liver transplant recipients. Liver Transpl 2014; 20: 679-686
• 808 Yazigi NA. Long term outcomes after pediatric liver transplantation. Pediatr Gastroenterol Hepatol Nutr 2013; 16: 207-218
• 809 Andries S, Casamayou L, Sempoux C. et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation 2001; 72: 267-272
• 810 Hernandez HM, Kovarik P, Whitington PF. et al. Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr 2001; 32: 131-136
• 811 Hadzic N, Quaglia A, Cotoi C. et al. Immunohistochemical phenotyping of the inflammatory infiltrate in de novo autoimmune hepatitis after liver transplantation in children. Pediatr Transplant 2012; 16: 501-510
• 812 Pongpaibul A, Venick RS, McDiarmid SV. et al. Histopathology of de novo autoimmune hepatitis. Liver Transpl 2012; 18: 811-818
• 813 Avitzur Y, Ngan BY, Lao M. et al. Prospective evaluation of the prevalence and clinical significance of positive autoantibodies after pediatric liver transplantation. J Pediatr Gastroenterol Nutr 2007; 45: 222-227
• 814 Demetris AJ, Bellamy C, Hübscher SG. et al. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant 2016; 16: 2816-2835